Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 09 Nov 2026, 03:17 UTC

19187

Studies in scope

all four open statuses

11790

Recruiting now

open to new participants

2028

Lead sponsors

across recruiting studies

Top sites

Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343

Trials with a site in Beijing

Status

Study

Lead sponsor

Phase

Enrol

Chinese sites

Start

Recruiting

AI Model for Assessing Cardiac Surgeons' Techniques

NCT06739005CABG-patients, CABG, Cardiovascular Surgery, Surgeons

China National Center for Cardiovascular Diseases

Observational

284

Beijing

2025-01-09

Recruiting

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy With GenSci122 in Participants With Advanced Solid Tumors

NCT06772415Advanced Solid Tumor

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 1

163

Beijing, Zhengzhou, Changsha, Nanjing, Jinan, Shanghai, Tianjin

2025-01-08

Recruiting

A Phase 2 Study of HX301 in Patients with High-grade Giloma

NCT06703255Glioma

DrugTemozolomide

Hangzhou Hanx Biopharmaceuticals, Ltd.

Phase 1/2

Beijing

2025-01-08

Recruiting

Assessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

NCT06768307SCLC, Extensive Stage, Immunotherapy, Chemotherapy, Radiotherapy

Peking University Cancer Hospital & Institute

Phase 2

Beijing

2025-01-07

Recruiting

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

NCT06712316Non-small Cell Lung Cancer

DrugsPumitamig·Pemetrexed·Paclitaxel·Carboplatin

BioNTech SE

Phase 2/3

1,580

Baoding, Beijing, Bengbu, Changchun, Changsha, Hangzhou, Jiamusi, Jinan

2025-01-07

Recruiting

Sirolimus Monotherapy in the Treatment of Antiphospholipid Antibody Related Thrombocytopenia

NCT06722586Antiphospholipid (aPL)-Positive, Thrombocytopaenia

DrugsRapamycin·Sirolimus

Peking University First Hospital

Phase 4

Changsha, Jinan, Chengdu, Ürümqi, Wenzhou, Beijing, Shanghai

2025-01-07

Recruiting

Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT06792253Relapsed/Refractory Diffuse Large B-Cell Lymphoma

DrugsIfupinostat Hydrochloride·Ifosfamide·Etoposide·Rituximab

BeBetter Med Inc

Phase 3

416

Beijing

2025-01-06

Recruiting

High-frequency SCS Versus SCS in the Treatment of Diabetic Peripheral Neuropathic Pain

NCT06158529Painful Diabetic Peripheral Neuropathy

Fan BiFa

Not applicable

Beijing

2025-01-06

Active, closed

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

NCT06760637Breast Cancer

DrugsAtirmociclib·Ribociclib·Abemaciclib·Palbociclib

Pfizer

Phase 3

1,035

Hefei, Beijing, Fuzhou, Foshan, Guangzhou, Nanning, Harbin, Wuhan

2025-01-06

Not yet open

TF-antigen Targeting Molecular Probe for PET Imaging in Solid Tumors

NCT06755086Solid Tumors

Drug18-FDG

Peking University Cancer Hospital & Institute

Observational

Beijing

2025-01-06

Not yet open

Oseltamivir and Baloxavir Marboxil for Prophylaxis Against Influenza Under a Hospital-based Setting

NCT06762587Influenza, Influenza Prophylaxis, Nosocomial Infection

DrugsOseltamivir·Baloxavir Marboxil

Capital Medical University

Not applicable

372

Beijing

2025-01-05

Recruiting

Safety and Pharmacokinetics of Y-4 Tablets in Healthy Subjects

NCT06935682Healthy Adult Male and Female Volunteers

DrugY-4 tables

Beijing Tiantan Hospital

Phase 1

Beijing

2025-01-04

Recruiting

Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients

NCT07036172Obesity Control

DrugWegovy

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Phase 3

460

Beijing

2025-01-03

Active, closed

A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise

NCT06716203Type 2 Diabetes Mellitus (T2DM)

DrugBGM0504 Administered

BrightGene Bio-Medical Technology Co., Ltd.

Phase 3

207

Beijing

2025-01-03

Recruiting

Endoscopic and Robotic NSM with Immediate Prosthesis Breast Reconstruction

NCT06748677Nipple-sparing Mastectomy, Immediate Prosthesis Reconstruction, Endoscopic Surgery, Robotic Surgery

Peking University People's Hospital

Observational

484

Beijing

2025-01-03

By invitation

Adaptive Blood Purification for the Treatment of Patients With Septic Shock

NCT06692036Septic Shock

Beijing Chao Yang Hospital

Not applicable

276

Beijing

2025-01-01

Recruiting

Mechanism Study of Yangyin Roujin Formula in the Treatment of Fibromyalgia Syndrome

NCT07736144Fibromyalgia Syndrome

Juan Jiao

Not applicable

Beijing

2025-01-01

Recruiting

HOPE From the Cerebellum: TMS-Induced Cognitive Recovery After Stroke

NCT06316557Post-stroke Cognitive Impairment, Ischemic Stroke

Zi-Xiao Li

Not applicable

Beijing

2025-01-01

Active, closed

RT for Adenocarcinoma/Adenosquamous Carcinoma

NCT07153952Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Radiotherapy

Peking Union Medical College Hospital

Phase 1/2

Beijing

2025-01-01

Recruiting

Assessment of the Efficacy and Safety of Fecal Microbiota Transplantation (FMT) in Patients With Major Depressive Disorder

NCT06692361Major Depressive Disorder (MDD), Depression - Major Depressive Disorder

DrugEscitalopram

Gang Wang

Not applicable

214

Wuhu, Beijing, Guangzhou, Shijiazhuang, Jining, Chengdu, Tianjin, Dali

2025-01-01

Recruiting

Multi-Modality Imaging Standard Cohort Of Cerebrovascular Disease

NCT06925178Cerebrovascular Disease

Beijing Tiantan Hospital

Observational

800

Beijing

2025-01-01

Recruiting

MMP14(MT1-MMP) Targeting Bicyclic Peptide Probe for PET Imaging in Solid Tumors

NCT06719856Solid Tumor

Drug18-FDG

Peking University Cancer Hospital & Institute

Observational

Beijing

2025-01-01

By invitation

Protective Effect of Probacine Against Negative Gut Metabolism and Organ Dysfunction After Cardiovascular Surgery (PANDA IV)

NCT04444362Cardiovascular Disease, Cardiopulmonary Bypass

Nanjing Medical University

Not applicable

500

Beijing, Guangzhou, Nanjing, Chengdu, Shanghai

2025-01-01

Recruiting

Study Safety and Efficacy of Deep Brain Stimulation (DBS) and Cervical Deep Lymphoid-venous Anastomosis (LVA) in Alzheimer's Disease

NCT07094438Alzheimer Disease

Chinese PLA General Hospital

Phase 1

Beijing

2025-01-01

Active, closed

Study on the Correlation Between Intraoperative Hypotension and Postoperative Myocardial Injury

NCT07094321Myocardial Injury After Noncardiac Surgery (MINS), Hypotension During Surgery

China-Japan Friendship Hospital

Observational

8,000

Beijing

2025-01-01

Not yet open

Protective Effect of Angong Niuhuang Against Negative Inflammatory Response and Neurologic Dysfunction After Cardiovascular Surgery

NCT06723366Cardio-pulmonary Bypass, Cardiovascular Surgery, Cerebral Protection, Brain Injury

DrugAngong Niuhuang Pill

Nanjing Medical University

Not applicable

120

Beijing, Nanjing

2025-01-01

Recruiting

Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial

NCT07101588Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Chinese PLA General Hospital

Phase 4

200

Beijing

2025-01-01

Recruiting

TACE Combined Surgery for the Resectable Huge HCC

NCT06898398Hepatocellular Carcinoma, Hepatic Chemotherapy, Liver Cancer, Surgery

Sun Yat-sen University

Observational

326

Beijing

2025-01-01

Not yet open

Dual-function Semirigid Thoracoscopy Versus Semirigid Thoracoscopy for the Diagnosis of Pleural Diseases: A Multicenter Open-label Randomized Controlled Trial

NCT06744725Pleural Diseases

China-Japan Friendship Hospital

Not applicable

334

Beijing

2025-01-01

Recruiting

Al18F-HER2-BCH PET in Breast Patients Treated With ADC Therapy

NCT06909604Breast Cancer

Peking University Cancer Hospital & Institute

Not applicable

Beijing

2025-01-01

Not yet open

Confocal Laser Endomicroscopy Assisted Endobronchial Ultrasound-guided- Transbronchial Mediastinal Cryobiopsy Via a Tunnel for Diagnosing Mediastinal Lymphadenopathy

NCT06741852Mediastinal Lymphadenopathy

China-Japan Friendship Hospital

Not applicable

Beijing

2025-01-01

Recruiting

Risk Prediction of Disease Progression in Early-Onset Coronary Atherosclerosis

NCT07316452Coronary Disease, Young Adult

Fu Wai Hospital, Beijing, China

Observational

10,000

Beijing

2025-01-01

Recruiting

Early Vitrectomy vs PRP in Early Proliferative Diabetic Retinopathy

NCT07586787Proliferative Diabetic Retinopathy (PDR)

Xiamen Ophthalmology Center Affiliated to Xiamen University

Not applicable

100

Beijing, Xiamen, Zhengzhou, Nanjing, Dalian

2025-01-01

Recruiting

Glycemic Improvement With Team, Technology, Education and Peer Resources in Type 1 Diabetes-GLITTER Study

NCT07097805Type 1 Diabetes (T1D)

Second Xiangya Hospital of Central South University

Not applicable

3,000

Beijing, Guangzhou, Shenzhen, Luoyang, Changsha, Nanjing, Shenyang, Chengdu

2025-01-01

Not yet open

Herombopag for the Prevention of Radio-chemotherapy Induced Thrombocytopenia in Cervical Cancer

NCT06745219Thrombopenia, Cervical Cancer, Radiotherapy Side Effect, Chemotherapeutic Toxicity

DrugHerombopag

Peking University Cancer Hospital & Institute

Phase 2

Beijing

2025-01-01

Not yet open

Study of MT027 in Patients with Brain, Meninges, and Spinal Cord Metastatic Solid Tumors

NCT06742593Brain (Nervous System) Cancers, Brain and Central Nervous System Tumors, Brain Tumors

DrugMT027 cells

Suzhou Maximum Bio-tech Co., Ltd.

Phase 1

Beijing

2025-01-01

Recruiting

Establishment of Clinical Prediction Model for Postoperative Symptomatic Spinal Epidural Hematoma

NCT06633848Spinal Epidural Hematoma

Peking University Third Hospital

Observational

2,000

Beijing

2025-01-01

Recruiting

Rectal Cancer Neoadjuvant Therapy-Real World Study

NCT07566559Rectal Cancer

Beijing Friendship Hospital

Observational

869

Beijing

2025-01-01

By invitation

A Study Comparing the Differences Between Young and Non-young Breast Cancer

NCT06793306Breast Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Observational

3,000

Beijing

2025-01-01

Recruiting

Bariatric Surgery Combined With GLP-1RA: A Multicenter Study.

NCT07732738Obesity

China-Japan Friendship Hospital

Not applicable

400

Xingtai, Zhengzhou, Baotou, Jinan, Datong, Kunming, Beijing

2025-01-01

Not yet open

The New Clinical Registration Trial of Interventional Treatment for Patients with Symptomatic Intracranial Artery Stenosis

NCT06740513Intracranial Atherosclerotic Stenosis (ICAS), Stroke

Xuanwu Hospital, Beijing

Observational

1,000

Beijing

2025-01-01

Recruiting

Zanubrutinib Combined With G-CVP in Previously Untreated FL

NCT06959732Follicular Lymphoma ( FL)

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2

Beijing

2025-01-01

Recruiting

Remimazolam and Emergence Delirium in Pediatrics

NCT07046364Pediatric, Neurosurgery, Sevoflurane Anesthesia, Remimazolam

DrugRemimazolam

Peking University First Hospital

Phase 4

248

Beijing

2025-01-01

Recruiting

Vitreous Zonule in Primary Angle-Closure Glaucoma

NCT07523139Primary Angle-Closure Glaucoma

Peking University People's Hospital

Observational

440

Beijing

2025-01-01

Recruiting

Multiple Omics Sequencing Technologies in Predicting the Efficacy and Monitoring the Recurrence of Non-Small Cell Lung Cancer

NCT07057102Non Small Cell Lung Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Observational

Beijing

2025-01-01

Not yet open

Prospective Cohort Study on Predicting the Progression of Diabetic Microangiopathy Using Multimodal Eye Imaging

NCT06727955Diabetic Retinopathy

Peking University Third Hospital

Observational

250

Beijing

2025-01-01

Not yet open

The Diagnostic Value of Bronchoscopic Needle-based Confocal Laser Endomicroscopy (nCLE) As a Real-time Detection Tool for Diagnosing Peripheral Lung Cancer: a Multi-centre Randomised Controlled Trial

NCT06739421Lung Cancer, Non-Small Cell, Lung Cancer, Small Cell

China-Japan Friendship Hospital

Not applicable

1,040

Beijing

2025-01-01

Active, closed

The Exploration of OX40 (CD134) Expression Levels in Sarcoma Specimens and Its Clinical Application in Prognosis Determination

NCT06751251Sarcoma, Biomarkers, Progression

Peking University People's Hospital

Observational

200

Beijing

2025-01-01

Not yet open

Protective Effect of PCSK9 Inhibitor Against Negative Inflammatory Response and Organ Dysfunction After Coronary Artery Bypass Grafting (PANDA VIII)

NCT06730802Myocardial Ischaemic Syndrome, Coronary Heart Disease

DrugBiweekly

Nanjing Medical University

Not applicable

400

Beijing, Nanjing

2025-01-01

Recruiting

Prospective Observational Cohort Study for Predicting Unruptured Intracranial Aneurysm Rupture Risk Using Blood Pressure Variability and 3D Structural Evolution

NCT07893574Unruptured Intracranial Aneurysm, Intracranial Aneurysm Rupture

Beijing Tiantan Hospital

Observational

2,000

Beijing

2025-01-01

Recruiting

A Multi-omics Sequencing-based Model for Predicting Efficacy and Dynamic Monitoring of Treatment in Small Cell Lung Cancer

NCT07026669Small Cell Lung Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Observational

Beijing

2025-01-01

Recruiting

Multi-Reader Multi-Case Trial Evaluating Computer-Aided Tool for Prognostic Prediction of Colorectal Liver Metastases

NCT07027605Colorectal Liver Metastasis (CRLM)

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Observational

166

Beijing

2025-01-01

Not yet open

CD147 Targeting Peptide Probe for PET Imaging in Solid Tumors

NCT06720298Solid Tumor

DrugFluorodeoxyglucose

Peking University Cancer Hospital & Institute

Observational

Beijing

2025-01-01

Not yet open

A Study of GNC-077 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors

NCT06755242Gastrointestinal Tumors, Solid Tumor

DrugGNC-077

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 1

Beijing

2025-01

Not yet open

Diagnostic Performance of Contrast-Enhanced Mammography

NCT06713915Mammography

ZHOU Yidong

Observational

600

Beijing

2025-01

Not yet open

An Exploratory Clinical Study of a Low-dose Buprenorphine Patch for the Treatment of Autism Spectrum Disorders

NCT06772324Autism Spectrum Disorder

Peking University Sixth Hospital

Not applicable

Beijing

2025-01

Recruiting

AI in Predicting Polyp Pathology and Endoscopic Classification

NCT06773832Colorectal Polyps

Peking Union Medical College Hospital

Observational

400

Beijing

2025-01

Not yet open

A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases

NCT06774664IgA Nephropathy

DrugSCTC21C

Sinocelltech Ltd.

Phase 1/2

Baotou, Beijing, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanning

2025-01

Not yet open

Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)

NCT06687174IgA Nephropathy (IgAN)

DrugMY008211A

Wuhan Createrna Science and Technology Co., Ltd

Phase 2

Beijing

2024-12-31

Recruiting

The Effects of Xuezhikang and Atorvastatin on Lipid in Patients With Dyslipidemia and Prediabetes

NCT06750783Prediabetic State (IGT)

DrugAtorvastatin

Beijing Tsinghua Chang Gung Hospital

Phase 4

398

Beijing

2024-12-31

Active, closed

A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT06707883Chronic Obstructive Pulmonary Disease

DrugTQC2731

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

Phase 2

258

Chuzhou, Hefei, Huainan, Beijing, Lanzhou, Foshan, Guangzhou, Jiangmen

2024-12-31

Not yet open

Tranexamic Acid with Intensive Blood Pressure Management in Ultra-Early Intracerebral Hemorrhage

NCT06760078Spontaneous Intracranial Hemorrhage, Hypertension

DrugTranexamic acid (TXA)

Xuanwu Hospital, Beijing

Phase 4

532

Beijing

2024-12-31

Recruiting

Effectiveness of Personalized Alternating Current Stimulation for Treating Cognitive Impairment in CNS Demyelination Patients

NCT06968039Multiple Sclerosis, Electric Stimulation

Xuanwu Hospital, Beijing

Not applicable

Beijing

2024-12-31

Recruiting

A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors

NCT06581419Advanced Malignant Neoplasm, Advanced or Metastatic Non-small Cell Lung Cancer

DrugIAP0971

SUNHO（China）BioPharmaceutical CO., Ltd.

Phase 1/2

Beijing

2024-12-31

Recruiting

Effect of Mobile-Based Home Cardiac Rehabilitation on Coronary Plaque

NCT07660419Coronary Artery Disease (CAD), Coronary Stenosis

China National Center for Cardiovascular Diseases

Not applicable

176

Beijing

2024-12-31

Recruiting

CVI Alterations in FD: a Prospective, Multicenter, Observational Cohort Study

NCT06512571Fabry Disease, Cardiac Variant

China National Center for Cardiovascular Diseases

Observational

300

Beijing

2024-12-31

Not yet open

Efficacy and Safety of Changkang Granules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver qi Affecting the Spleen Pattern)

NCT06753890Diarrhea-predominant Irritable Boewl Syndrome

Tasly Pharmaceutical Group Co., Ltd

Phase 3

520

Baoding, Beijing, Changsha, Chengde, Chengdu, Guangzhou, Hangzhou, Kaifeng

2024-12-30

Active, closed

A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight Subjects

NCT06728124Obesity/Overweight

DrugBofanglutida

Gan & Lee Pharmaceuticals.

Phase 3

630

Beijing

2024-12-30

Not yet open

Targeted TDCS Intervention for Internet Gaming Disorder

NCT06759051Internet Gaming Disorder

Peking University

Not applicable

180

Beijing

2024-12-30

Recruiting

Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors

NCT07415863Advanced/Metastatic Solid Tumors

DrugSYS6043

CSPC Megalith Biopharmaceutical Co.,Ltd.

Phase 1/2

820

Beijing

2024-12-30

Not yet open

Photoplethysmography (PPG) Algorithm With Smartwatch in Evaluation of Atrial Fibrillation Burden

NCT06686940Atrial Fibrillation (AF)

Beijing Anzhen Hospital

Observational

10,000

Beijing

2024-12-30

Active, closed

A Clinical Study of HT-101 and/or HT-102 in Patients With Chronic Hepatitis B Virus Infection

NCT07183306Chronic Hepatitis B

DrugsHT-101·HT-102

Suzhou HepaThera Biotech Co., Ltd.

Phase 1/2

Beijing, Xiamen, Guangzhou, Qingyuan, Shanghai, Chengdu

2024-12-30

Not yet open

QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension

NCT06716970Essential Hypertension

DrugSacubitril / Valsartan

Wuhan Createrna Science and Technology Co., Ltd

Phase 3

810

Beijing

2024-12-30

Recruiting

Effectiveness of Personalized Alternating Current Stimulation for Treating Emotional Disorders in CNS Demyelination Patients

NCT06933537Idiopathic Inflammatory Demyelinating Disorders of the Central Nervous System

Xuanwu Hospital, Beijing

Not applicable

Beijing

2024-12-29

Recruiting

A Phase Ib Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion

NCT06740019Malignant Pleural Effusions (Mpe)

DrugJMKX000197

Jemincare

Phase 1

Beijing

2024-12-28

Active, closed

Efficacy and Safety of ZVS101e in Patients With Bietti 's Crystalline Dystrophy

NCT06743646Bietti Crystalline Corneoretinal Dystrophy, Bietti Crystalline Dystrophy

DrugZVS101e

Chigenovo Co., Ltd

Phase 3

Beijing, Guangzhou, Zhengzhou, Chengdu, Tianjin

2024-12-27

Recruiting

Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors

NCT06566079Malignant Mesothelioma, Metastatic Malignant Solid Tumor, Advanced Solid Tumor

InSilico Medicine Hong Kong Limited

Phase 1/2

160

Zhengzhou, Shanghai, Beijing, Guangzhou

2024-12-27

Recruiting

BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases

NCT06794008Systemic Lupus Erythematosus, Inflammatory Myopathy, Systemic Sclerosis (SSc), ANCA-associated Vasculitis

Peking University People's Hospital

Phase 2

Beijing

2024-12-26

Recruiting

A Phase I Study of HY-2003 in the Subjects With Excessive Submental Fat Accumulation

NCT06756490Moderate or Severe Submental Fullness

Sichuan Huiyu Pharmaceutical Co., Ltd

Phase 1

Beijing, Xi'an

2024-12-26

Recruiting

A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)

NCT07547787Locally Advanced Unresectable or Metastatic Gastric Cancer

Akeso

Observational

610

Beijing

2024-12-26

Active, closed

A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)

NCT06593522MTAP-deleted NSCLC

DrugAnvumetostat

Amgen

Phase 2

Beijing, Fuzhou, Zhengzhou, Wuhan, Changsha, Changchun, Jinan, Shanghai

2024-12-26

Recruiting

A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies

NCT06971523Solid Tumor, Lymphoma

CytosinLab Therapeutics Co., Ltd.

Phase 1/2

224

Beijing

2024-12-25

Recruiting

The Regression Pattern of Primary Lesions in Lung Cancer After Definitive Radiotherapy

NCT06692972Lung Cancer

China-Japan Friendship Hospital

Observational

500

Beijing, Wuhan

2024-12-25

Active, closed

Endovascular Treatment or Standard Medical Care for Cerebral Venous Sinus Thrombosis(ESCORT)

NCT06583889Cerebral Venous Sinus Thrombosis

DrugHeparin

Beijing Tiantan Hospital

Not applicable

224

Beijing

2024-12-24

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation

NCT06556394Amyotrophic Lateral Sclerosis

Ractigen Therapeutics.

Phase 1

Beijing, Chengdu, Hangzhou

2024-12-24

Recruiting

Sirolomus Adjuvant Treatment of Focal Refractory Epilepsy (SATFRE)

NCT06719791Epilepsy, Drug Resistant

DrugSirolimus

Xuanwu Hospital, Beijing

Early Phase 1

Beijing

2024-12-23

Recruiting

Clinical and Metabolomics Studies on the Improvement of Ovarian Reserve by Acupoint Photodynamic Therapy and Traditional Chinese Medicine Treatment

NCT07376824Diminished Ovarian Reserve (DOR)

Peking Union Medical College Hospital

Phase 3

Beijing

2024-12-20

Recruiting

A Clinical Study to Evaluate the Efficacy, Tolerability, and Safety of Bempedoic Acid

NCT06780410Primary Hyperlipidemia

DrugBempedoic acid

Gan & Lee Pharmaceuticals.

Phase 3

240

Beijing

2024-12-20

Active, closed

Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid Tumors

NCT06806046Solid Tumors, Colorectal Cancer

DrugM9140

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 1

Beijing, Guangzhou, Hangzhou

2024-12-20

Recruiting

A Study of GC101 TIL in Advanced Melanoma

NCT06703398Melanoma

DrugsAutologous Tumor Infiltrating Lymphocytes·Cisplatin

Shanghai Juncell Therapeutics

Phase 2

Beijing

2024-12-20

Recruiting

A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

NCT06500702Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion

DrugsBrivekimig·Frexalimab·Rilzabrutinib

Sanofi

Phase 2

Beijing, Chengdu, Shanghai

2024-12-19

Active, closed

Efficacy and Safety of OsrhCT and Dimethicone Emulsion Before Upper Endoscopy on Visualization of the Gastric Mucosa.

NCT06722664Gastric Mucosal Lesion

DrugDimethicone

Healthgen Biotechnology Corp.

Phase 2

336

Beijing, Wuhan, Hohhot

2024-12-19

Recruiting

Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

NCT06736574Heart Failure, Heart Failure With Reduced Ejection Fraction

Cytokinetics

Phase 3

1,800

Beijing, Chongqing, Lanzhou, Guangzhou, Shenzhen, Nanning, Harbin, Luoyang

2024-12-19

Recruiting

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

NCT06656494Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS)

DrugsICP-248·Azacitidine

Beijing InnoCare Pharma Tech Co., Ltd.

Phase 1

266

Hefei, Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Suzhou, Nanchang

2024-12-18

Not yet open

Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer

NCT06752408Non Small Cell Lung Cancer

DrugsAlmonertinib·Osimertinib

Peking Union Medical College Hospital

Phase 2

316

Beijing

2024-12-17

Recruiting

Multicenter Real-World Cohort Study Evaluating the Impact of Early Intensive Lipid-Lowering Therapy on the Prognosis of Acute Coronary Syndrome Patients(ELITE-ACS)

NCT06738758Acute Coronary Syndromes

DrugBiweekly

Yun Dai Chen

Observational

6,000

Beijing

2024-12-16

Recruiting

Study on the Mechanism of Cognitive Impairment in Patients with Moyamoya Disease

NCT06832839Moyamoya Disease

Beijing Tiantan Hospital

Observational

360

Beijing

2024-12-16

Recruiting

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

NCT06679101Multiple Myeloma, Newly Diagnosed Multiple Myeloma

DrugsBelantamab mafodotin·Daratumumab·Lenalidomide·Dexamethasone

GlaxoSmithKline

Phase 3

520

Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing, Shanghai

2024-12-16

Recruiting

Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection

NCT07028970Multiple Myeloma

Nanjing IASO Biotechnology Co., Ltd.

Observational

1,500

Beijing, Tianjin, Wuhan, Zhengzhou

2024-12-15

Recruiting

Effects of Transcranial Electrical Stimulation on Cognitive Impairment in CNS Inflammatory Demyelinating Diseases

NCT07029386Idiopathic Inflammatory Demyelinating Disorders of the Central Nervous System

Xuanwu Hospital, Beijing

Not applicable

Beijing

2024-12-15

Recruiting

Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Colorectal Cancer

NCT06718738Colorectal Cancer (CRC)

Beijing Immunochina Medical Science & Technology Co., Ltd.

Phase 1

Beijing

2024-12-15

Recruiting

Study on Evaluating the Effectiveness of Statins in the Treatment of Moyamoya Disease

NCT06817434Moyamoya Disease

Beijing Tiantan Hospital

Observational

330

Beijing

2024-12-15

Active, closed

A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

NCT06628310Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma

DrugsBudigalimab·Telisotuzumab Adizutecan·Fluorouracil·Leucovorin

AbbVie

Phase 2

185

Beijing, Langfang, Harbin, Wuhan, Hangzhou

2024-12-13

Recruiting

TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma

NCT06740370Hepatocellular Carcinoma, Transcatheter Arterial Chemoembolization, Anti-PD1 Antibody, Lenvatinib

DrugsVenetocalx·Lenvatinib

Sun Yat-sen University

Not applicable

Beijing

2024-12-13

Recruiting

Normobaric Oxygen in AIS Transferred for EVT

NCT06666764Ischemic Stroke

Capital Medical University

Phase 3

1,500

Beijing, Fuzhou, Ningde, Putian, Zhangzhou, Guangzhou, Hezhou, Cangzhou

2024-12-13

Recruiting

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

NCT06750094Colorectal Neoplasms

DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Erbitux·Avastin

Janssen Research & Development, LLC

Phase 3

700

Beijing, Changchun, Changsha, Chengdu, Ganzhou, Guangzhou, Hangzhou, Harbin

2024-12-12

Recruiting

A Study of SIGX1094R in Patients With Advanced Solid Tumors

NCT06739291Advanced Solid Tumors

Signet Therapeutics

Phase 1

102

Beijing

2024-12-12

Recruiting

A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-6204 (SKB535) for Injection in Participants With Advanced Solid Tumors

NCT06726369Advanced Solid Tumors

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 1

142

Xiamen, Wuhan, Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Linyi

2024-12-12

Recruiting

A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)

NCT06716606Connective Tissue Diseases

DrugBelimumab

GlaxoSmithKline

Phase 3

514

Beijing, Chengdu, Hangzhou, Mianyang, Shanghai, Shenyang, Zhuzhou

2024-12-12

Recruiting

Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer

NCT06584032Advanced Endometrial Cancer

DrugsFruquintinib·Doxorubicin·Sintilimab·Paclitaxel

Hutchmed

Phase 3

412

Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Changsha

2024-12-12

Recruiting

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.

NCT05421858Candidemia, Candidiasis, Invasive

DrugsCaspofungin·Fosmanogepix·Fluconazole

Basilea Pharmaceutica

Phase 3

450

Beijing, Bengbu, Chengdu, Guangzhou, Hangzhou, Lishui, Liuzhou, Nanchang

2024-12-11

Active, closed

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06588855Moderately to Severely Active Ulcerative Colitis

DrugAfimkibart

Hoffmann-La Roche

Phase 3

350

Beijing, Kunming, Changsha, Chengdu, Guangzhou, Hangzhou, Huizhou, Nanning

2024-12-11

Recruiting

Impact of Severe Obstructive Sleep Apnea-Hypopnea Syndrome on Auditory-Cognitive Processing

NCT07039500Obstructive Sleep Apnea, Auditory Processing Disorder

Peking University First Hospital

Observational

100

Beijing

2024-12-11

Not yet open

Evaluating an Insulin Pump for Time in Range (TIR) in Patients with Type 1 Diabetes

NCT06741943Type 1 Diabetes Mellitus, Insulin Pump, Time in Range

Tao Yuan，MD

Not applicable

Beijing

2024-12-11

Not yet open

Orthopedic Intelligent Navigation System in the Treatment of Fresh Femoral Neck Fractures

NCT06713018Fracture of Neck of Femur

Chinese PLA General Hospital

Not applicable

300

Beijing

2024-12-10

Recruiting

Clinical Study of a Novel Sliding Compression Locking Plate in the Treatment of Fresh Femoral Neck Fractures

NCT06713291Fracture of Femoral Neck

Chinese PLA General Hospital

Not applicable

1,150

Beijing

2024-12-10

Recruiting

Establishment and Clinical Transformation of ADC Drug Efficacy Evaluation System for Breast Cancer Based on Molecular Imaging

NCT06715020Breast Cancer

DrugFluorodeoxyglucose

Peking University Cancer Hospital & Institute

Not applicable

Beijing

2024-12-10

Not yet open

Medial Enhancement Technique for the Treatment of Old Femoral Neck Fractures

NCT06713031Fracture of Neck of Femur

Chinese PLA General Hospital

Not applicable

400

Beijing

2024-12-10

Recruiting

Ultrasound-guided Thermal Ablation for Papillary Thyroid Carcinoma

NCT06733740Papillary Thyroid Cancer

Chinese PLA General Hospital

Observational

3,000

Beijing

2024-12-10

By invitation

A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Airway Mucus Hypersecretion

NCT06820749Asthma Bronchiale, Bronchiectasis, Chronic Obstructive Pulmonary Disease (COPD)

DrugHSK31858

Haisco Pharmaceutical Group Co., Ltd.

Phase 2

309

Beijing

2024-12-10

Recruiting

iGlarLixi CGM Study in Chinese T2D Individuals After OADs

NCT06671587Type 2 Diabetes (T2D)

DrugsIGlarLixi·Insulin glargine

Sanofi

Phase 4

678

Beijing

2024-12-10

Recruiting

A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors

NCT06625593Advanced Solid Tumor

BeOne Medicines

Phase 1

168

Bengbu, Hefei, Beijing, Fuzhou, Xiamen, Nanning, Shijiazhuang, Harbin

2024-12-09

Recruiting

Ultrasound-guided Thermal Ablation for Bethesda III/IV Thyroid Nodules

NCT06733753Thyroid Nodule

Chinese PLA General Hospital

Observational

600

Beijing

2024-12-09

Recruiting

Long-term Follow-up Study of AL-001 Ophthalmic Injection in Subjects with WAMD

NCT06718816Wet Age-related Macular Degeneration (wAMD)

Beijing Anlong Biopharmaceutical Co., Ltd.

Observational

Beijing

2024-12-09

Recruiting

Predictive Value of Myelodysplastic Syndrome Stem Cells Determined by Multiparameter Flow Cytometry

NCT06569095Myelodysplastic Syndromes

Peking University People's Hospital

Observational

163

Beijing, Wuhan, Zhengzhou

2024-12-09

Recruiting

Ultrasound-guided Thermal Ablation for Benign Thyroid Nodules

NCT06729762Thyroid Nodule (Benign)

Chinese PLA General Hospital

Observational

1,500

Beijing

2024-12-09

Recruiting

Ultrasound-guided Thermal Ablation for Recurrent Thyroid Cancer

NCT06733766Recurrent Thyroid Cancer

Chinese PLA General Hospital

Observational

300

Beijing

2024-12-09

Recruiting

Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

NCT06597019Familial Hypercholesterolemia - Heterozygous

DrugInclisiran

Novartis Pharmaceuticals

Phase 3

Beijing, Shanghai

2024-12-09

Recruiting

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

NCT06679140COVID-19 SARS-CoV-2 Infection

DrugIbuzatrelvir

Pfizer

Phase 3

2,330

Chizhou, Beijing, Xiamen, Guangzhou, Nanning, Changsha, Nanchang, Changchun

2024-12-08

Active, closed

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia

NCT06834932Dyslipidaemia

DrugsRosuvastatin 1·Rosuvastatin 2·AZD0780

AstraZeneca

Phase 2/3

432

Baotou, Beijing, Bengbu, Changchun, Changde, Changsha, Changzhou, Chengdu

2024-12-06

Recruiting

A Phase III Clinical Trial for Efficacy and Safety Evaluation of JP-1366 Tablets on Reflux Esophagitis

NCT06850480Reflux Esophagitis (RE)

Livzon Pharmaceutical Group Inc.

Phase 3

356

Beijing

2024-12-05

Active, closed

Nipocalimab in Moderate to Severe Sjogren's Disease

NCT06741969Sjogrens Syndrome

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

655

Beijing, Changsha, Changzhou, Chengdu, Dazhou, Ganzhou, Guangzhou, Guiyang

2024-12-04

Recruiting

Hydrocortisone in Hormone Replacement Therapy for Large Pituitary Neuroendocrine Tumors

NCT06679816Pituitary Adenoma, Pituitary Neuroendocrine Tumor

Beijing Tiantan Hospital

Phase 4

882

Beijing

2024-12-04

Recruiting

Exploration of the Dynamic Changes and Mechanisms of the Immune Microenvironment in Advanced Colorectal Cancer Treated With IBI363 Combination Therapy

NCT06946745Immunotherapy

jianming xu

Observational

Beijing

2024-12-02

Not yet open

Tofacitinib in Patients With Amyotrophic Lateral Sclerosis

NCT06689982Amyotrophic Lateral Sclerosis

DrugTofacitinib

Beijing Tiantan Hospital

Early Phase 1

Beijing

2024-12-01

Recruiting

Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer

NCT06926179Lung Cancer (NSCLC), Neoadjuvant Immunotherapy, Radiotherapy, Lung Surgery

Peking University Cancer Hospital & Institute

Observational

500

Beijing, Hohhot, Kunming

2024-12-01

Not yet open

Research on the Application of Patient Navigation-based Management Model of Patients After LEEP

NCT06695871Cervical Intraepithelial Neoplasias

Peking University People's Hospital

Not applicable

128

Beijing

2024-12-01

Not yet open

A Randomized Controlled, Open, Single-center Clinical Study Evaluating the Efficacy and Safety of Umbilical Cord Blood Mononuclear Cells in Patients with Refractory Immune Effector Cell-related Hemocytopenia

NCT06729320Refractory Immune Effector Cell-related Hemocytopenia

Beijing GoBroad Hospital

Not applicable

Beijing

2024-12-01

Recruiting

Impact of Recombinant Humanized Type III Collagen on the Immediate and Long-term Effects of Breast Tumor Surgery

NCT06725082Breast Cancer, Collagen Protein

Peking University People's Hospital

Phase 1

Beijing

2024-12-01

Recruiting

tSCS Combined With Rehabilitation Training in Treating Paraplegic Patients After SCI

NCT07907952Spinal Cord Injury, Paraplegia, Spinal

Beijing Tsinghua Chang Gung Hospital

Not applicable

Beijing

2024-12-01

Recruiting

Pre-Anesthesia Visit: Analysis of Coverage Rate of Visit Content and Surgical Patients' Understanding of Information

NCT06735183To Assess the Coverage of Anesthesiology Residents' Explanations of the Content of the Visit, Patients' Understanding of the Content of the Anesthesia Approach Through the Physician's Explanations

Anshi Wu

Observational

110

Beijing

2024-12-01

Recruiting

Evaluation of Targeted Biopsy Plus Sextant Biopsy in Diagnosis of Prostate Cancer

NCT06684652Prostate Cancer

Peking University First Hospital

Not applicable

300

Beijing

2024-12-01

Recruiting

Adaptive Radiotherapy for Genitourinary Cancers

NCT07324798Prostate Cancer (Post Prostatectomy), Bladder Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Not applicable

Beijing

2024-12-01

Recruiting

Minimal Vitrectomy Surgery for Epiretinal Membrane

NCT07019896Epiretinal Membrane, Macular Edema (ME), Nuclear Cataract

Peking Union Medical College Hospital

Not applicable

140

Beijing

2024-12-01

Not yet open

A Novel Classification of Sagittal Spinal Alignment to Aid Surgical Planning for Adult Spinal Deformity

NCT06470152Adult Spinal Deformity, Sagittal Deformity, Sagittal Alignment, Sagittal Imbalance

Xuanwu Hospital, Beijing

Not applicable

200

Beijing

2024-12-01

Recruiting

Effects of Sleep Restriction and Stimulus Control in Chronic Insomnia Patients

NCT06658184Chronic Insomnia

Xuanwu Hospital, Beijing

Not applicable

Beijing

2024-12-01

Recruiting

Blinatumomab Combined With Low-dose DLI as Maintenance Therapy After Transplantation for B-ALL

NCT07677878ALL (Acute B-Lymphoblastic Leukemia)

DrugBlinatumomab

Liping Dou

Phase 1

Beijing

2024-12-01

Recruiting

SCS Therapy for Patients With Bladder and Bowel Dysfunction After SCI

NCT07511244Bladder and Bowel Dysfunction, SCI - Spinal Cord Injury

Beijing Tsinghua Chang Gung Hospital

Not applicable

Beijing

2024-12-01

Recruiting

The Role of AAT After Abdominal Surgery Based on RWS

NCT06580197Acupuncture, Ear, Gastroparesis

Peking Union Medical College Hospital

Observational

159

Beijing

2024-12-01

Recruiting

Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDAR/anti-LGI1 Encephalitis

NCT06510283Anti-N-Methyl-D-Aspartate Receptor Encephalitis

Beijing Tongren Hospital

Phase 2

Beijing

2024-12-01

Recruiting

Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC

NCT06725498Head and Neck Squamous Cell Carcinoma

DrugsAlbumin-Bound Paclitaxel·Cisplatin

Beijing Tongren Hospital

Phase 2

Beijing

2024-12-01

Active, closed

The Impact of Targeted Temperature Management Duration on Thrombin Function in Cardiac Arrest Patients

NCT06543849Targeted Temperature Management, Cardiac Arrest, Thrombin Function, Treatment Duration

Tang Ziren

Not applicable

Beijing

2024-12-01

Recruiting

Risk Stratification and MRD-driven Maintenance for MM After ASCT

NCT06697483Multiple Myeloma

DrugsDaratumumab·Lenalidomide

Peking University People's Hospital

Not applicable

100

Beijing, Harbin

2024-12-01

Recruiting

Effects of Cognitive Correction and Stimulus Control in Chronic Insomnia Patients

NCT06658158Chronic Insomnia

Xuanwu Hospital, Beijing

Not applicable

Beijing

2024-12-01

Recruiting

Laser Acupuncture for Idiopathic Bell's Palsy

NCT06732622Bell Palsy

Beijing Tongren Hospital

Not applicable

360

Beijing

2024-12-01

Active, closed

Treatment Duration of IPA

NCT06583512Invasive Aspergillosis, Antifungal Therapy

Peking University People's Hospital

Observational

Beijing

2024-12-01

Recruiting

Cohort Study on the Prognosis and Influencing Factors in Elderly Patients With Hip Fractures in Multicenter of China

NCT07847164Hip Fractures (i.e. Femoral Neck or Intertrochanteric Hip Fractures)

Beijing Hospital

Observational

10,000

Beijing

2024-12-01

Recruiting

Rectal Indomethacin as Early Treatment for Acute Pancreatitis (INDOMAP Trial)

NCT03547232Acute Pancreatitis, Complication, Mortality Rate, Organ Failure, Multiple

DrugIndomethacin

Peking Union Medical College Hospital

Phase 4

1,504

Beijing, Guiyang, Baoding, Harbin, Dengzhou, Nanyang, Huaian, Nantong

2024-12-01

Active, closed

Efficacy of Liposomal Bupivacaine Scalp Nerve Block for Postoperative Pain Management After Supratentorial Craniotomy

NCT07344181Postoperative Care

Beijing Tiantan Hospital

Not applicable

118

Beijing

2024-12-01

By invitation

Clinical Study of Rhythmic Auditory Stimulation for Gait Disorders

NCT06837038Hemiplegia Due to Stroke, Parkinson Disease, Parkinsonian Syndrome

YiCheng Zhu

Not applicable

Beijing

2024-12-01

Not yet open

A Phase II Study of SHR-4602 as Montherapy or in Combination With Other Anti-tumor Therapies in Advanced Solid Tumors

NCT06704828Advanced Solid Tumors

DrugSHR-4602

Shanghai Hengrui Pharmaceutical Co., Ltd.

Phase 2

Beijing

2024-12

Recruiting

CD147 Targeting Nanobody Probe for PET Imaging in Solid Tumors

NCT06646952Solid Tumor

DrugFluorodeoxyglucose

Hua Zhu

Observational

Beijing

2024-12

Recruiting

Toripalimab Plus Actinomycin-D As Fist-Line Treatment for GTN with FIGO Score 7

NCT06020755Gestational Trophoblastic Neoplasia

DrugsActinomycin-D·Toripalimab

Peking Union Medical College Hospital

Phase 2

Beijing

2024-12

Not yet open

Research on the Monitoring, Pathogen Screening, and Diagnostic System for Unexplained and Newly Emerging Acute Hepatitis

NCT06653140Hepatitis of Unknown Aetiology

Minghui Li

Observational

100

Beijing

2024-12

Not yet open

A Study for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions

NCT06731829For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions

DrugGadobutrol

Jiangsu HengRui Medicine Co., Ltd.

Phase 2

Beijing

2024-12

Not yet open

Combined Aerobic Exercise and Cognitive Training in Seniors at Increased Risk for Alzheimer's Disease

NCT05163626Alzheimer Disease

Xuanwu Hospital, Beijing

Not applicable

200

Beijing

2024-12

Not yet open

Combined Aerobic Exercise and Cognitive Training in Seniors With Genetic Susceptibility for Alzheimer's Disease

NCT05163067Alzheimer Disease

Xuanwu Hospital, Beijing

Not applicable

200

Beijing

2024-12

Not yet open

Pralatrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory/Relapsed Peripheral T-cell Lymphoma

NCT06671717Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma

Peking University People's Hospital

Not applicable

Beijing

2024-12

Recruiting

Temporal Interference for Drug Resistant Epilepsy

NCT06708143Drug Resistant Epilepsy

Xuanwu Hospital, Beijing

Not applicable

Beijing

2024-11-30

Recruiting

Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer

NCT06459687Cervical Cancer

DrugsCisplatin/Carboplatin·Paclitaxel·Bevacizumab

Lee's Pharmaceutical Limited

Phase 3

440

Hefei, Beijing, Wuhan, Changsha, Hangzhou

2024-11-28

Active, closed

A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China

NCT06666855Open Angle Glaucoma, Ocular Hypertension

Santen Pharmaceutical Co., Ltd.

Phase 3

345

Beijing, Guangzhou, Guiyang, Hangzhou, Heilongjiang, Jinan, Lanzhou, Luoyang

2024-11-28

Active, closed

A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of VSA003 in Chinese HoFH Patients

NCT06712771Homozygous Familial Hypercholesterolemia (HoFH)

DrugZodasiran

Visirna Therapeutics HK Limited

Phase 3

Beijing

2024-11-27

Recruiting

A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor Patients

NCT07260305Advanced or Metastatic Solid Tumors

DrugsKGX101·Envafolimab

Kangabio AUSTRALIA LTD PTY

Phase 1

Beijing, Shanghai

2024-11-27

Recruiting

A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients

NCT06564324Non Small Cell Lung Cancer

DrugsTaletrectinib·Crizotinib

Nuvation Bio Inc.

Phase 3

194

Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Shijiazhuang, Zhengzhou

2024-11-27

Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

NCT06627647Non-squamous Non-small Cell Lung Cancer

DrugsRilvegostomig·Pemetrexed·Keytruda·Cisplatin

AstraZeneca

Phase 3

1,160

Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou

2024-11-27

Active, closed

Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort

NCT06649721Drug-resistant Tuberculosis, Pulmonary Tuberculosis, Rifampin-resistant Tuberculosis

DrugsClofazimine·Delamanid·Bedaquiline·Levofloxacin

Huashan Hospital

Phase 3

120

Hefei, Beijing, Xiamen, Nanning, Liupanshui, Shijiazhuang, Harbin, Jiamusi

2024-11-27

By invitation

Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.

NCT06763965Recurrent High-grade Glioma

DrugBioTTT001

Beijing Bio-Targeting Therapeutics Technology Co., Ltd

Phase 1/2

Beijing

2024-11-26

Recruiting

A Study of ES014 in Subjects With Advanced Solid Tumors

NCT06543056Advanced Solid Tumor

DrugES014

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2

Beijing

2024-11-25

Recruiting

Atrial Shunt for the Treatment of Heart Failure With Reduced Ejection Fraction

NCT07820410Heart Failure With Reduced Ejection Fraction (HFrEF)

Beijing Anzhen Hospital

Phase 2/3

208

Beijing

2024-11-25

Recruiting

Safety, Tolerability, and Pharmacokinetics of Single Doses of HC022 in Healthy Subjects.

NCT06657703Systemic Lupus Erythematosus

DrugHC022

HC Biopharma Inc.

Phase 1

Beijing

2024-11-25

Recruiting

Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases

NCT06688799Autoimmune Diseases

Beijing GoBroad Hospital

Phase 1/2

Beijing

2024-11-23

Active, closed

A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps

NCT06639295Sinusitis, Nasal Polyps

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Phase 3

243

Beijing

2024-11-22

Recruiting

A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration

NCT06959615Advanced Solid Tumor

DrugJAB-23E73

Jacobio Pharmaceuticals Co., Ltd.

Phase 1/2

334

Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Langfang, Haerbin, Zhengzhou

2024-11-22

Recruiting

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

NCT06532006Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer, HER2-positive Gastric Cancer

DrugsHLX22·Trastuzumab·Capecitabine·Oxaliplatin

Shanghai Henlius Biotech

Phase 3

550

Baise City, Beijing, Bengbu, Changchun, Changsha, Changzhi, Changzhou, Chengdu

2024-11-22

Recruiting

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

NCT06617325Systemic Lupus Erythematosus

UCB Biopharma SRL

Phase 3

450

Baotou, Beijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Guangzhou

2024-11-21

Active, closed

A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)

NCT06698042Lung Cancer, Non-Small Cell Lung Cancer

Drugs) Berahyaluronidase alfa·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Huizhou, Jiangmen, Liuzhou

2024-11-21

Recruiting

A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma

NCT06767800Gastroesophageal Adenocarcinoma

DrugsTQB2102·Penpulimab·Benmelstobart

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Phase 2

204

Fuyang, Lu'an, Maanshan, Beijing, Chongqing, Fuzhou, Lanzhou, Wuwei

2024-11-21

Recruiting

Radiolabelled Nectin-4 Targeted LMW Probe PET/CT in Patients With Lung Lesions

NCT06648317Lung Cancer, Non-Small Cell, Lung Infection

Peking University Cancer Hospital & Institute

Observational

Beijing

2024-11-21

Recruiting

Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease

NCT06682169Graft-versus-host Disease

DrugsRovadicitinib·Mycophenolate Mofetil·Imatinib·Methotrexate

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

182

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Nanning

2024-11-20

Recruiting

Analysis of 18F-XTR006 PET Imaging in Cognitively Normal Subjects, and Patients With MCI and AD

NCT07115238Alzheimer Disease, Neurofibrillary Tangle

Sinotau Pharmaceutical Group

Phase 3

354

Beijing

2024-11-20

Recruiting

The Treatment of Sepsis Induced Myocardial Dysfunction With Yiqilishui Formula

NCT06686355Sepsis Induced Myocardial Dysfunction

Dongzhimen Hospital, Beijing

Phase 2

Beijing

2024-11-20

Recruiting

Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation

NCT06956001EGFR, NSCLC (Advanced Non-small Cell Lung Cancer)

DrugsFirmonertinib Mesilate·Pemetrexed·Cisplatin·Carboplatin

Allist Pharmaceuticals, Inc.

Phase 3

300

Beijing, Shandong

2024-11-19

Active, closed

Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

NCT06578247Leukemia

DrugQuizartinib

Daiichi Sankyo

Phase 3

700

Beijing, Changchun, Changsha, Chongqing, Guangzhou, Jinan, Nanchang, Nanjing

2024-11-19

Recruiting

Moderated Hypofractionated Online Adaptive Radiotherapy in Cervical Cancer

NCT06641635Cervical Cancer, Adaptive Radiotherapy

Peking Union Medical College Hospital

Phase 3

440

Beijing

2024-11-19

Recruiting

Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia

NCT07514936Newly Diagnosed Acute Myeloid Leukemia (AML), Elderly Patients

DrugsAclacinomycin·Azacytidine·Chidamide·Cytarabine

Chinese PLA General Hospital

Phase 3

120

Beijing

2024-11-18

Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

NCT06692738Non-small Cell Lung Cancer

DrugsRilvegostomig·Nab-paclitaxel·Keytruda·Paclitaxel

AstraZeneca

Phase 3

1,160

Beijing, Changchun, Changde, Changsha, Chengdu, Chongqing, Dalian, Guangzhou

2024-11-18

Recruiting

Mts105 for Advanced Hepatocellular Carcinoma

NCT06689540Liver Cancer, Adult, Metastatic Liver Cancers, HCC - Hepatocellular Carcinoma, Hepatocellular Carcinoma (HCC)

Shen Lin

Phase 1

Beijing

2024-11-18

Recruiting

NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor

NCT06134960Gastric Cancer, Pancreatic Cancer, Solid Tumor

Peking University

Phase 1

Beijing

2024-11-16

Recruiting

A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia

NCT06568471Hypercholesterolemia, Dyslipidemias, Primary Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia

DrugLerodalcibep

Hasten Biopharmaceutical Co., Ltd.

Phase 3

210

Beijing, Guangzhou, Shijiazhuang, Daqing, Changsha, Nanchang, Binzhou, Heze

2024-11-16

Not yet open

EGFR Mutation Targeting Molecular Probe for PET Imaging

NCT06641674Cancer

Peking University Cancer Hospital & Institute

Observational

Beijing

2024-11-15

Active, closed

A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

NCT06616194Migraine

DrugRimegepant

Pfizer

Phase 3

636

Beijing, Chongqing, Guangzhou, Jingzhou, Wuhan, Changsha, Suzhou, Wuxi

2024-11-15

Active, closed

Ultrasound-based Artificial Intelligence for Classification of Carpal Tunnel Syndrome

NCT06697392Carpal Tunnel Syndrome (CTS), Ultrasound, Artificial Intelligence (AI)

Peking University People's Hospital

Observational

500

Beijing

2024-11-15

Not yet open

Genes, Proteins, and Metabolites in Drug-resistant Epilepsy (DRE) Patients

NCT06665880Drug Resistant Epilepsy, Traumatic Brain Injury Without Open Intracranial Wound

Xuanwu Hospital, Beijing

Observational

Beijing

2024-11-15

Recruiting

Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Polychondritis

NCT06873100Relapsing Polychondritis

DrugUpadacitinib

Peking University People's Hospital

Phase 1/2

Beijing

2024-11-15

Not yet open

CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma

NCT06641453Hepatocellular Carcinoma (HCC)

DrugsFludarabine Phosphate·Cyclophosphamide

Chinese PLA General Hospital

Phase 1/2

Beijing

2024-11-15

Recruiting

Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL

NCT06880913Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Peking University People's Hospital

Phase 1/2

Beijing

2024-11-14

Recruiting

ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis

NCT06775860Atopic Dermatitis

DrugICP-332

Beijing InnoCare Pharma Tech Co., Ltd.

Phase 3

552

Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shaoguan

2024-11-14

Active, closed

A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)

NCT06680921Locally Advanced or Metastatic Breast Cancer

DrugsSIM0270·Exemestane·Everolimus·Fulvestrant

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 3

482

Bengbu, Hefei, Maanshan, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou

2024-11-14

Not yet open

A Phase I Clinical Trial Evaluating the Safety, Tolerability and Pharmacokinetics of AAPB for Injection

NCT06679998Acute Ischemic Stroke (AIS)

Jiangsu Kanion Pharmaceutical Co., Ltd

Phase 1

Beijing

2024-11-14

Recruiting

A Clinical Research About CD70-targeted CAR-NKT Cells Therapy in Subjects with Advanced Malignant Solid Tumors

NCT06728189Advanced Malignant Solid Tumors

Peking University Cancer Hospital & Institute

Phase 1

Beijing

2024-11-14

Recruiting

Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer

NCT06711471Gastric Cancer Adenocarcinoma Metastatic

DrugCamrelizumab

LIN YANG

Phase 2

Beijing

2024-11-14

Recruiting

Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma

NCT06714383Osteosarcoma

DrugsLobaplatin·Pirarubicin·Trilaciclib

Peking University People's Hospital

Phase 2

Beijing

2024-11-13

By invitation

Multicenter Prospective Cohort Study of Hypertriglyceridemia Acute Pancreatitis

NCT06976099Acute Pancreatitis (AP), Hypertriglyceridemia Acute Pancreatitis

Peking Union Medical College Hospital

Observational

1,000

Beijing, Guangzhou, Zunyi, Harbin, Changsha, Nanjing, Yangzhou, Dalian

2024-11-13

Active, closed

A Real-world Study to Assess Safety of OZURDEX® (Dexamethasone Intravitreal Implant) in Adult Participants With Diabetic Macular Edema in China

NCT06548568Diabetic Macular Edema

AbbVie

Observational

110

Beijing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Dalian, Xi'an, Qingdao

2024-11-13

Recruiting

Effectiveness of Digital Cognitive Behavioral Therapy for the Treatment of Depression: a Real-world Study

NCT06831435Depression, Bipolar Affective Disorder, Schizophenia Disorder, Psychiatric &Amp;or Mood Disorder

Peking University

Not applicable

325

Beijing

2024-11-13

Recruiting

Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor

NCT07433283Tumor, Solid, Lung Cancer, Pancreas Cancer, Thyroid Cancer

Sichuan Enray Pharmaceutical Sciences Company

Phase 1/2

Beijing, Hunan, Chongqing, Fuzhou, Haikou, Heilongjiang, Shanghai, Chengdu

2024-11-12

Recruiting

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

NCT06632457Metabolic Dysfunction Associated Steatohepatitis

Boehringer Ingelheim

Phase 3

1,590

Beijing, Changchun, Changsha, Changzhou Shi, Chengdu, Chongqing, Foshan, Fuzhou

2024-11-12

Recruiting

Family-Based Moyamoya Susceptibility and Early Detection

NCT07517354Moyamoya Disease

Beijing Tiantan Hospital

Observational

700

Beijing

2024-11-12

Recruiting

Improved Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Protocol for the Treatment of Epstein Barr Virus T/NK Lymphoproliferative Disease (EBV-T/NK LPD) and Prevention of Post Transplant Graft-versus-host Disease

NCT07029958EBV-T/NK LPD

Beijing Children's Hospital

Phase 4

Beijing

2024-11-12

Active, closed

A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

NCT06537414Chronic Hepatitis B Virus Infection, Hepatitis B

DrugBepirovirsen

GlaxoSmithKline

Phase 2

283

Beijing, Chengdu, Guangzhou, Shanghai

2024-11-11

Recruiting

IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)

NCT06647862Chronic Myelomonocytic Leukemia

DrugsTimdarpacept·Azacitidine

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Phase 3

170

Hefei, Beijing, Chongqing, Lanzhou, Nanning, Guangzhou, Shenzhen, Zhujiang

2024-11-11

Active, closed

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)

NCT06719141Developmental and Epileptic Encephalopathy

DrugBexicaserin

Longboard Pharmaceuticals

Phase 3

367

Beijing, Guangzhou, Shenzhen Shi, Wuhan, Shanghai Shi

2024-11-11

Recruiting

Development and Application of Precision Treatment Strategies for Common Mental Disorders

NCT06729541Depression - Major Depressive Disorder, Schizophrenia Disorders, Bipolar Disorder (BD)

Peking University

Not applicable

600

Beijing

2024-11-11

Recruiting

Evaluating the Short-term Efficacy of Two Oscillation Techniques in Hypersecretive Mechanically Ventilated Patients

NCT06675942Hypersecretive Mechanically Ventilated Patients

Capital Medical University

Not applicable

Beijing

2024-11-10

Recruiting

Baricitinib in the Treatment of Intestinal Behçet's Syndrome

NCT06849908Behcet Syndrome, Intestinal Type

DrugsHumira·Baricitinib·Adalimumab

Peking Union Medical College Hospital

Phase 2

Beijing

2024-11-08

Recruiting

Safety and Effectiveness of the Peripheral Balloon-Expandable Covered Stent System for Iliac Artery Stenosis/Occlusion. (SELECT)

NCT06605209Peripheral Artery Disease (PAD)

Zhejiang Zylox Medical Device Co., Ltd.

Not applicable

130

Beijing

2024-11-08

Active, closed

A Study of the RNA Tumor Vaccine Targeting MICA/B in Patients With Advanced Solid Tumors

NCT06610227Advanced Solid Tumors

NING LI

Early Phase 1

Beijing

2024-11-08

Recruiting

Early Antiplatelet Administration After Intravenous Thrombolysis for Acute Ischemic Stroke (TREND-IVT)

NCT06548971Acute Ischemic Stroke, Cerebral Infarction

DrugAspirin

Capital Medical University

Phase 3

1,184

Bengbu, Bozhou, Huaibei, Suzhou, Beijing, Haidian, Pinggu, Tongzhou

2024-11-07

Active, closed

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

NCT06676319Asthma

DrugsBudesonide/Formoterol·Lunsekimig

Sanofi

Phase 2

556

Beijing, Changchun, Chengde, Chengdu, Foshan, Guangzhou, Guiyang, Hangzhou

2024-11-07

Not yet open

The Survey of Treatment and Metabolic Status of Type 1 Diabetes Mellitus (T1DM).

NCT06606509Type1 Diabetes Mellitus

Nanjing First Hospital, Nanjing Medical University

Observational

1,000

Anqing, Bengbu, Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Quanzhou

2024-11-07

Recruiting

89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study

NCT06750419Clear Cell Renal Cell Carcinoma

Telix Pharmaceuticals (Innovations) Pty Limited

Phase 3

Beijing, Hangzhou, Hubei, Shanghai, Suzhou, Tianjin, Wuxi, Zhejiang

2024-11-06

Recruiting

Evaluation of Long-term Isokinetic Training of Knee Joint

NCT06674473Knee Injuries and Disorders

Peking University Third Hospital

Not applicable

Beijing

2024-11-06

Recruiting

Seniors Integrated Longitudinal cardioVascular Evaluation of Coronary Heart Disease: a Multicenter, Prospective Registry in China (SILVER-China)

NCT06880575Coronary Arterial Disease (CAD), ELDERLY PEOPLE

Beijing Hospital

Observational

10,139

Beijing

2024-11-06

Recruiting

A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma

NCT06566586B-cell Lymphoma

DrugTQB3702

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2

Beijing, Lanzhou, Guangzhou, Guigang, Nanning, Harbin, Anyang, Puyang

2024-11-06

Recruiting

A Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HRS-4508 Monotherapy in Patients With Advanced or Metastatic Solid Tumors

NCT06598735Advanced Solid Tumors

DrugHRS-4508

Jiangsu HengRui Medicine Co., Ltd.

Phase 1

290

Beijing

2024-11-05

Not yet open

Minimally Invasive Atlantoaxial Lateral Mass Joint Fusion (MIS-PALF) As a Surgical Treatment of Atlantoaxial Dislocation

NCT06678711Atlantoaxial Dislocation

Peking University Third Hospital

Not applicable

Beijing

2024-11-04

Recruiting

Fufang Congrong Yizhi Capsules (FCYC) of Cognitive Impairment After Intracerebral Hemorrhage

NCT06673602Cognitive Impairment, Intracerebral Hemorrhage

Qinhuangdao Hospital of Traditional Chinese Medicine

Phase 4

200

Beijing, Qinhuangdao, Kaifeng, Jinan, Weifang, Kunming

2024-11-04

Recruiting

Evaluating Modulation Effects of Temporal Interference Using SEEG

NCT06663969Deep Brain Stimulation, Drug Resistant Epilepsy

Xuanwu Hospital, Beijing

Not applicable

Beijing

2024-11-04

Recruiting

Longitudinal Cohort of Thrombosis and Hemostasis Diseases

NCT06727669Immune Thrombocytopenia, Thrombotic Thrombocytopenic Purpura, Hemophilia A, Acquired, Disseminated Intravascular Coagulation

Peking University People's Hospital

Observational

3,000

Beijing, Zhengzhou, Chongqing

2024-11-01

Recruiting

Effect of WBT for CI With Depression

NCT06968013Chronic Insomnia, Depression Disorders

Xuanwu Hospital, Beijing

Not applicable

Beijing

2024-11-01

Recruiting

Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

NCT06684600Esophageal Squamous Cell Carcinoma

DrugsDalpiciclib·Pyrotinib

Peking University

Phase 2

Beijing

2024-11-01

Recruiting

Effects of Tai Chi on Chronic Insomnia Disorder Combined With Hyperarousal/Anxiety

NCT06967974Chronic Insomnia

Xuanwu Hospital, Beijing

Not applicable

Beijing

2024-11-01

Recruiting

Ba Duan Jin for CI With Hyperarousal/Anxiety

NCT06969079Mind-Body Therapies, Insomnia Chronic

Xuanwu Hospital, Beijing

Not applicable

Beijing

2024-11-01

Recruiting

The Effect of Standard Cognitive-behavioral Therapy+Transcranial Alternating Current on Refractory Insomnia Disorder

NCT06969040Insomnia

Xuanwu Hospital, Beijing

Not applicable

Beijing

2024-11-01

Recruiting

Digital Early Warning System for Acute Lung Injury in Liver Surgery

NCT07070362Acute Lung Injury(ALI), Liver Cirrhosis, ARDS, Human, MASLD

Beijing Tsinghua Chang Gung Hospital

Observational

3,000

Beijing, Chongqing, Qingdao

2024-11-01

Recruiting

Memory Training in Insomnia With Cognitive Impairment

NCT06969066Cognitive Therapy/Methods, Insomnia Chronic, Cognitive Dysfunction

Xuanwu Hospital, Beijing

Not applicable

Beijing

2024-11-01

Not yet open

Smart Technology Facilitated Patient-centered Venous Thromboembolism Management

NCT06350344Venous Thromboembolism, Digital Health, Health Education

Navy General Hospital, Beijing

Not applicable

2,353

Beijing

2024-11-01

Recruiting

Effects of Relaxation Training and Stimulus Control in Chronic Insomnia Patients

NCT06658171Chronic Insomnia

Xuanwu Hospital, Beijing

Not applicable

Beijing

2024-11-01

Not yet open

A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway

NCT06614751Solid Cancers, BRCA Mutation, HRD Cancer, Breast Cancer

DrugDAT-2645

Danatlas Pharmaceuticals Co., Ltd

Phase 1

112

Beijing, Beijjing

2024-11-01

Recruiting

Research on Clinical Recovery and Maintenance Strategies for CHB

NCT06803368Chronic Hepatitis b, Hepatitis B Vaccine

Beijing Municipal Administration of Hospitals

Not applicable

285

Beijing

2024-11-01

Recruiting

Impact of Analytic-integrative Cognitive Behavioural Therapy on Acute Insomnia Disorder (Stress)

NCT06967922Acute Insomnia Disorder

Xuanwu Hospital, Beijing

Not applicable

Beijing

2024-11-01

Recruiting

Effect of MIT for CI With Anxiety

NCT06969053Chronic Insomnia, Anxiety Disorders

Xuanwu Hospital, Beijing

Not applicable

Beijing

2024-11-01

Recruiting

Validating a Medical AI Fine-Tuning Platform for Major Diseases

NCT07795645Chronic Gastritis, Gastric Cancer (GC), Coronary Artery Disease, Stroke

Beijing Friendship Hospital

Observational

96,000

Beijing

2024-11-01

Recruiting

Evaluation of the Efficacy of MACitentan in the Treatment of CoronaryMICrovascular Angina (MACMIC)

NCT06811831Coronary Microvascular Angina, Macitentan

DrugMacitentan

China-Japan Friendship Hospital

Early Phase 1

Beijing

2024-11-01

Recruiting

Using Multiparametric Flow Cytometry to Detect Peripheral Blood and Bone Marrow Leukaemia Stem Cells for Relapse Prediction in P-AML

NCT06452732Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia

Peking University People's Hospital

Observational

283

Beijing

2024-11-01

Active, closed

Evaluating the Effectiveness of Intervention Based on the Model of Occupational Harmony in Patients With Sleep Disorders

NCT06558929Circadian Rhythm Sleep-Wake Disorder

Peking University First Hospital

Not applicable

Beijing

2024-11-01

By invitation

The Effectiveness of Interventions Targeting Self-Perception of Aging in Older Adults with Subjective Cognitive Decline

NCT06622889Subjective Cognitive Decline (SCD)

Zheng Li

Not applicable

Beijing

2024-11-01

Not yet open

Intelligent Analysis and Clinical Validation of Cerebral Small Vessel Disease on Magnetic Resonance Imaging：A Multi-center Study

NCT06667635Cerebral Small Vessel Disease

Chinese PLA General Hospital

Observational

1,000

Beijing

2024-11-01

Not yet open

Drug Eluting Stenting and Short Dual Antiplatelet Therapy for Preventing Recurrent Stroke in Vertebral Stenosis Registry Study

NCT06683300Vertebral Artery Stenosis

Beijing Tiantan Hospital

Observational

520

Beijing

2024-11

Not yet open

A Clinical Trial to Evaluate the Safety and Tolerability of TQB3911 Tablets in Patients With BCR::ABL Fusion Gene Positive Leukemia

NCT06672263Chronic Myelogenous Leukemia

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Phase 1

120

Beijing, Nanning, Zhengzhou, Shanghai, Hangzhou

2024-11

Not yet open

Identification Of High-risk Coronary Plaques By Multimodal Intravascular Imaging

NCT06681155Coronary Arterial Disease (CAD), Acute Coronary Syndromes

Chinese PLA General Hospital

Observational

500

Shenzhen, Wuhan, Changchun, Xi'an, Ürümqi, Hangzhou, Beijing

2024-11

Recruiting

Prone Position Assessed by 3D EIT

NCT07083973ARDS (Acute Respiratory Distress Syndrome), Respiratory Failure

Peking Union Medical College Hospital

Observational

Beijing

2024-10-31

Recruiting

Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML

NCT06741722AML, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia

Beijing 302 Hospital

Phase 2

Beijing

2024-10-31

Recruiting

A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)

NCT06650852Chronic Hepatitis B Virus (HBV) Infection

DrugsElebsiran·Peg-IFNα

Brii Biosciences Limited

Phase 2

250

Beijing, Guangzhou, Shenzhen, Shanghai, Chengdu, Hangzhou

2024-10-31

Recruiting

A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors

NCT06609187Breast Cancer, Solid Tumor

DrugGNC-077

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 1

Beijing

2024-10-30

Recruiting

A First-in-Human Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of a Novel CRISPR RNA-editing Therapy in Patients with Mecp2 Duplication Syndrome, a Rare Orphan Disease (HERO)

NCT06615206MECP2 Duplication Syndrome

HuidaGene Therapeutics Co., Ltd.

Not applicable

Beijing

2024-10-30

Recruiting

Evaluation of Safety, Efficacy, and Pharmacokinetics of BT-114143 Injection in Patients With Abnormal Uterine Bleeding

NCT07169214Abnormal Uterine Bleeding

DrugBT-114143

ScinnoHub Pharmaceutical Co., Ltd.

Phase 1

Beijing

2024-10-30

Active, closed

A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

NCT06711900Non-Small Cell Lung Cancer

DrugsSacituzumab tirumotecan·Pemetrexed·Cisplatin·Carboplatin

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 3

432

Beijing, Changchun, Changcun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou

2024-10-30

Recruiting

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

NCT06663332Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile

DrugGuselkumab

Janssen Research & Development, LLC

Phase 3

196

Beijing, Changzhou, Hangzhou, Shanghai, Shenyang

2024-10-29

By invitation

Adaptive Cognitive Training on Cognitive Function in Elderly Diabetes Patients in the Community

NCT06524388Cognition, Diabetes Mellitus, Type 2, Aging

Fanfan Zheng

Not applicable

120

Beijing

2024-10-29

Recruiting

An Open-label, Multi-center, Dose-escalation and Cohort Expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of ACR246 in Patients With Advanced Solid Tumors

NCT06238401Advanced Solid Tumors

Hangzhou Adcoris Biopharmacy Co., Ltd

Phase 1

Beijing, Zhejiang, Shandong, Shanghai

2024-10-29

By invitation

Adaptive Cognitive Training on Cognitive Function in Elderly Hypertension Patients in the Community

NCT06512922Hypertension, Condition, Aging

Peking University

Not applicable

120

Beijing

2024-10-29

Recruiting

Rapid dFLC Response Predict CHR in AL Amyloidosis

NCT06627309Systemic AL Amyloidosis

DrugsDara·Bortezomib·Dexamethasone·Cyclophosphamide

Peking University People's Hospital

Observational

Beijing, Harbin, Nanjing, Shenyang, Xi'an

2024-10-26

Active, closed

A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)

NCT06653153Alzheimer's Disease

DrugRemternetug

Eli Lilly and Company

Phase 3

1,400

Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hefei, Jinan, Luoyang

2024-10-24

Recruiting

A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

NCT06644118Multiple Myeloma

Zhejiang University

Phase 1

Beijing, Xi’an, Hangzhou

2024-10-23

Recruiting

Value of Super-resolution Ultrasonography in Differentiating Benign and Malignant Lymph Nodes

NCT07155954Lymphadenopathy, Lymphnode Metastasis, Lymphoma, Lymphatic Tuberculosis

Peking University Third Hospital

Observational

779

Beijing

2024-10-23

Recruiting

A Prospective Study Evaluating the Impact of Conservative Management on Retained Products of Conception and EMV

NCT06862089Retained Products of Conception, Miscarriage, Conservative Management

Fu Xing Hospital, Capital Medical University

Observational

120

Beijing

2024-10-23

Recruiting

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

NCT06629779Metastatic Castration-Resistant Prostate Cancer

DrugsMevrometostat·Xtandi·Enzalutamide

Pfizer

Phase 3

900

Wuhu, Beijing, Fuzhou, Guangzhou, Shantou, Guilin, Xinxiang, Zhengzhou

2024-10-22

Not yet open

Levofloxacin Plus Metronidazole Suppositories Versus Levofloxacin Co-administered with Metronidazole Tablets in Chronic Endometritis

NCT06650540IVF

DrugLevofloxacin

Peking University Third Hospital

Not applicable

800

Beijing

2024-10-22

Recruiting

A Study in Chinese Patients With Acquired Blepharoptosis

NCT06683651Blepharoptosis

Santen Pharmaceutical Co., Ltd.

Phase 3

180

Hefei, Beijing, Shantou, Guiyang, Zhengzhou, Ha’erbin, Wuhan, Xiangyang

2024-10-22

Active, closed

A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

NCT06551324Metastatic Castrate Resistant Prostate Cancer (mCRPC)

DrugsMevrometostat·Xtandi·Taxotere·Enzalutamide

Pfizer

Phase 3

609

Wuhu, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Guilin, Wuhan

2024-10-21

Active, closed

A Clinical Trial With KJ103 in Anti-GBM Disease

NCT06607016Anti-Glomerular Basement Membrane Disease

DrugCyclophosphamide

Shanghai Bao Pharmaceuticals Co., Ltd.

Phase 2

Beijing

2024-10-21

Recruiting

Opioid-free Anesthesia Protocol for Neurosurgical Supratentorial Tumor Resection

NCT06607029Supratentorial Tumors

Beijing Tiantan Hospital

Not applicable

170

Beijing

2024-10-21

Recruiting

A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension

NCT06554301Pulmonary Arterial Hypertension

China National Center for Cardiovascular Diseases

Phase 1

Beijing

2024-10-20

Not yet open

Clinical Study of Radiotherapy Combined With Camrelizumab and Apatinib in the Treatment of Liver Cancer Patients .

NCT06632522Liver Cancer

DrugCamrelizumab and apatinib

Beijing Tsinghua Chang Gung Hospital

Phase 2

Beijing

2024-10-20

Recruiting

TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas

NCT06640582Brain Tumor, Brain Metastases, Brain Cancer, Glioma

DrugsTumor Infiltrating Lymphocytes·Aldesleukin·Fludarabine·Cyclophosphamide

Essen Biotech

Phase 1/2

Beijing

2024-10-20

Recruiting

Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors

NCT06598800Advanced Solid Tumor

BeOne Medicines

Phase 1

153

Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Shijiazhuang, Harbin, Wuhan

2024-10-18

Active, closed

Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation

NCT06780930Residual or Recurrent Grade 2 IDH Mutant Glioma

DrugVorasidenib

Servier

Phase 3

Shenzhen, Chengdu, Beijing, Shanghai, Xi'an

2024-10-18

Recruiting

Correlation Analysis of POD and pNCD in Elderly Patients With Gastrointestinal Neoplasms

NCT06466096Postoperative Delirium, Postoperative Neurocognitive Disorder, Gastrointestinal Surgery

Xuanwu Hospital, Beijing

Observational

165

Beijing

2024-10-18

Recruiting

PRospective Observation on CErebral microvaScular Structure and Function

NCT06579677Cerebral Microvascular Dysfunction, Cerebral Small Vessel Diseases, Cognitive Dysfunction, Cerebrovascular Disorders

Beijing Tiantan Hospital

Observational

3,500

Beijing

2024-10-18

Recruiting

Efficacy and Safety Study of Endovascular Treatment of Asymptomatic Carotid Artery Stenosis

NCT06899399Asymptomatic Carotid Artery Stenosis

Beijing Tiantan Hospital

Not applicable

982

Beijing

2024-10-18

Recruiting

A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

NCT06544499Primary Immune Thrombocytopenia (ITP)

DrugEfgartigimod

argenx

Phase 3

Beijing, Bengbu, Chengde, Hohhot, Huai'an, Huizhou, Tianjin, Wuhan

2024-10-18

Recruiting

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

NCT06662786Colorectal Neoplasms

DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Erbitux·Irinotecan

Janssen Research & Development, LLC

Phase 3

1,000

Beijing, Changchun, Changsha, Guangzhou, Hangzhou, Harbin, Huizhou, Nanchang

2024-10-18

Active, closed

A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)

NCT06643481Amyotrophic Lateral Sclerosis (ALS)

DrugVHB937

Novartis Pharmaceuticals

Phase 2

251

Beijing

2024-10-17

Recruiting

A Study of BL-B01D1 in Patients With Recurrent Glioblastoma

NCT06598787Recurrent Glioblastoma

DrugIza-bren

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 2

Beijing

2024-10-17

Recruiting

Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus

NCT06585514Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)

Beijing GoBroad Hospital

Phase 1/2

Beijing

2024-10-17

Recruiting

Long-term Impact of Inhaled Tobramycin for Pseudomonas Aeruginosa Eradication in Bronchiectasis (ERASE II)

NCT06760273Bronchiectasis Adult

Shanghai Pulmonary Hospital, Shanghai, China

Observational

364

Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Zhanjiang, Nanning

2024-10-16

Not yet open

An IIT Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal Injection of SNUG01 in Patients with Amyotrophic Lateral Sclerosis

NCT06645197Amyotrophic Lateral Sclerosis (ALS)

DrugSNUG01

Peking University Third Hospital

Early Phase 1

Beijing, Fujian, Nanjing, Chengdu, Hangzhou

2024-10-16

Active, closed

MRD in PAAD Adjuvant Therapy

NCT06867146The Role of Molecular Residual Disease in the Treatment Strategy and Prognosis Prediction of Pancreatic Cancer Patients Undergoing Adjuvant Therapy, Molecular Residual Disease, Pancreatic Cancer, Adjuvant Therapy

Peking Union Medical College Hospital

Not applicable

Beijing

2024-10-15

Not yet open

To Evaluate Efficacy and Safety of TopicalKX-826 Solution in Chinese Male Patients With Androgenetic Alopecia

NCT06622824Androgenetic Alopecia (AGA)

Suzhou Kintor Pharmaceutical Inc,

Phase 2/3

756

Beijing

2024-10-15

Recruiting

Efficacy of Self-expandable and Balloon-expandable Valves in Patients With Ascending Aortic Dilation

NCT06743568Aortic Stenosis, Ascending Aortic Dilatation

China National Center for Cardiovascular Diseases

Not applicable

100

Beijing, Shenzhen, Kunming

2024-10-15

By invitation

LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer

NCT06876675Non-Small Cell Lung Cancer, Hyperlipidemia

DrugLorlatinib

Peking University Third Hospital

Observational

167

Beijing

2024-10-15

Active, closed

Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14)

NCT06629818Light Chain (AL) Amyloidosis

DrugsDaratumumab·Venetoclax·Dexamethasone

Peking Union Medical College Hospital

Phase 2

Beijing

2024-10-15

Recruiting

Acupuncture for ADHD: Acupoint Data Mining, Clinical Effectiveness, and Interviews to Explore Treatment Outcomes.

NCT06860763Acupuncture, ADHD - Attention Deficit Disorder With Hyperactivity, Children, Interview

The Third Affiliated Hospital of Beijing University of Chinese Medicine

Not applicable

120

Beijing

2024-10-15

Recruiting

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

NCT06632444Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis

Boehringer Ingelheim

Phase 3

1,800

Beijing, Changchun, Changsha, Changzhou Shi, Chengdu, Chongqing, Foshan, Fuzhou

2024-10-14

Active, closed

Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC

NCT06827145Non-Small-Cell Lung Cancer

DrugsBozitinib·Vebreltinib·Osimertinib

National Cancer Center, China

Phase 2

Beijing

2024-10-14

Active, closed

A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer

NCT06561607Breast Cancer

DrugTQB2102

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

542

Bengbu, Hefei, Beijing, Quanzhou, Zhangzhou, Lanzhou, Wuwei, Guangzhou

2024-10-11

Recruiting

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

NCT06581432Solid Tumours

DrugZongertinib

Boehringer Ingelheim

Phase 2

588

Beijing, Changsha, Hangzhou, Hefei, Nanchang, Nanjing, Shanghai, Wuhan

2024-10-11

Active, closed

Regular Physical Exercise in Patients With Symptomatic Intracranial Arterial Stenosis

NCT06615726Ischemic Stroke, Transient Ischemic Attack

Capital Medical University

Phase 3

1,300

Fuyang, Huainan, Suzhou, Wuhu, Beijing, Chongqing, Zhangzhou, Foshan

2024-10-10

Recruiting

ZR-MTX for PIOL Phase II Trial

NCT06973811Primary Intraocular Lymphoma

DrugsZanubrutinib·Methotrexate·Rituximab

Peking Union Medical College Hospital

Phase 2

Beijing

2024-10-10

Recruiting

Hypofractionated Postoperative Regional Nodal Irradiation for Patients With Intermediate-risk Breast Cancer

NCT06757621Breast Carcinoma

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 3

3,142

Beijing

2024-10-10

Recruiting

Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma

NCT06348264Salivary Gland Neoplasm Duct

DrugsLeuprolide Acetate·Rezvilutamide

Peking University First Hospital

Phase 2

Beijing

2024-10-10

By invitation

Clinical Study on the Combination of Xiaoyu Zhitong Formula and Lymphatic Drainage Technique to Improve the Symptoms of Knee Pain and Swelling in Cold Dampness Obstruction Type

NCT06911437Knee Osteoarthritis (OA)

tang jie

Observational

100

Beijing

2024-10-10

Recruiting

A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus

NCT06535412Systemic Lupus Erythematosus

DrugIMC-002

ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.

Phase 1/2

218

Beijing

2024-10-10

Recruiting

Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis

NCT06418594HER2-negative Breast Cancer Brain Metastases

DrugsApatinib·Adebrelimab·Etoposide

Beijing 302 Hospital

Phase 2

Beijing

2024-10-10

Recruiting

Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular Edema

NCT07515079Diabetic Macular Edema (DME)

DrugLucentis

Bio-Thera Solutions

Phase 3

406

Beijing, Chongqing, Lanzhou, Guangzhou, Shantou, Shenzhen, Nanning, Zunyi

2024-10-09

By invitation

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SSS39 Injection in Healthy Chinese Subjects

NCT07057726Safety and Tolerability in Healthy Volunteers

Shenyang Sunshine Pharmaceutical Co., LTD.

Phase 1

Beijing

2024-10-09

Recruiting

A Bioequivalence Study of PP3M in Patients With Schizophrenia

NCT07493551Schizophrenia

DrugPaliperidone Palmitate

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Not applicable

260

Beijing

2024-10-09

Active, closed

Identify Effective Doses of LY01021 in Controlled Ovarian Hyperstimulation (COH) for Female Subjects Undergoing Assisted Reproductive Technology (ART)

NCT07236476Assisted Reproduction

Luye Pharma Group Ltd.

Phase 2

Beijing

2024-10-09

By invitation

Application of Generative Artificial Intelligence in Perioperative Personalized Rehabilitation for Older Adults With Lung Cancer

NCT07915193Lung Neoplasms

Peking University Cancer Hospital & Institute

Not applicable

150

Beijing

2024-10-09

Active, closed

A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

NCT06470048Diffuse Cutaneous Systemic Sclerosis

DrugIanalumab

Novartis Pharmaceuticals

Phase 2

201

Nanning, Zhengzhou, Chengdu, Ningbo, Beijing, Tianjin

2024-10-09

Active, closed

An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).

NCT06335979Systemic Lupus Erythematosus, SLE

DrugPIT565

Novartis Pharmaceuticals

Phase 1

Beijing

2024-10-08

Active, closed

To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

NCT06552520Atopic Dermatitis

DrugTQH2722

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

Phase 3

500

Bengbu, Tongling, Wuhu, Beijing, Chongqing, Xiamen, Guangzhou, Shenzhen

2024-10-08

Recruiting

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

NCT06561386Non-small Cell Lung Cancer

DrugsRelatlimab·Pemetrexed·Nivolumab·Cisplatin

Bristol-Myers Squibb

Phase 3

1,000

Hefei, Beijing, Chongqing, Wanzhou, Fuzhou, Guangzhou, Huizhou, Liuzhou

2024-10-07

Recruiting

Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma

NCT06644430Advanced Hepatocellular Carcinoma, Lung Cancer, Oligometastasis, Ablation

Sun Yat-sen University

Observational

470

Beijing

2024-10-04

Active, closed

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06417814Metastatic Non-small Cell Lung Cancer

DrugsTagrisso·Dato-DXd·Osimertinib·Pemetrexed

AstraZeneca

Phase 3

768

Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Deyang, Ganzhou

2024-10-04

Recruiting

A Study of BG-C477 in Participants With Advanced Solid Tumors

NCT06596473Advanced Solid Tumors

DrugTislelizumab

BeOne Medicines

Phase 1

310

Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Jiamusi, Zhengzhou

2024-10-03

Recruiting

VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS

NCT06471946Higher-risk Myelodysplastic Syndromes

DrugVenetoclax

Navy General Hospital, Beijing

Phase 1/2

Beijing

2024-10-01

Recruiting

Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia

NCT06581081Relapsed Adult ALL, B-cell Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL

Peking University People's Hospital

Not applicable

130

Beijing

2024-10-01

Recruiting

HAIC Compared With TACE in Huge Hepatocellular Carcinoma

NCT06641713Hepatocellular Carcinoma, Hepatic Chemotherapy, Liver Cancer

Sun Yat-sen University

Observational

664

Beijing

2024-10-01

Recruiting

dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma

NCT06609863Advanced Hepatocellular Carcinoma, Atezolizumab, Bevacizumab, Chemotherapy

Sun Yat-sen University

Not applicable

Beijing

2024-10-01

Recruiting

Effect of Hypophosphatemia on Neuro-excursion Efficiency During Mechanical Ventilator Weaning

NCT06754670Mechanical Ventilation, Weaning Failure, Hypophosphatemia

Peking Union Medical College

Observational

Beijing

2024-10-01

Recruiting

Multitarget Stereotactic Electrophysiological Recording and Stimulation for Tourette Syndrome

NCT06889480Tourette Syndrome, Deep Brain Stimulation

Beijing Tiantan Hospital

Not applicable

Beijing

2024-10-01

Recruiting

Impact of Frequency-specific Subthalamic Nucleus Subregion Stimulation on Inhibitory Control in Parkinson's Disease

NCT07022522Parkinson Disease, Deep Brain Stimulation

Beijing Tiantan Hospital

Not applicable

Beijing

2024-10-01

Recruiting

Application of Non-inductive Intelligent Physical Sign Monitoring Equipment Based on Flexible Electronic Devices in the Diagnosis and Treatment of Cardiovascular Diseases

NCT07466056Cardiovascular Disease

Beijing Anzhen Hospital

Observational

1,100

Beijing

2024-10-01

Not yet open

All-cause and Diseases-specific Mortality of High-risk HPV Infection

NCT06631495HPV Infection

Peking Union Medical College Hospital

Observational

100,000

Beijing

2024-10-01

Recruiting

Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas

NCT06176027Relapsed Peripheral T-Cell Lymphomas, Refractory Peripheral T-Cell Lymphomas

DrugAzacytidine

Navy General Hospital, Beijing

Phase 1/2

Beijing

2024-10-01

Recruiting

Transaxillary TAVR With Solely Echocardiography Guidance

NCT07035847Aortic Stenosis

Chinese Academy of Medical Sciences, Fuwai Hospital

Not applicable

Beijing

2024-10-01

By invitation

Efficacy and Safety of Tofacitinib in Refractory Blau Syndrome

NCT06660329Blau Syndrome

Peking Union Medical College Hospital

Phase 4

Beijing

2024-10-01

Not yet open

Exosome-based OCS Scores for Predicting Ovarian Cancer Recurrence

NCT06558019Ovarian Cancer

Lei Li

Observational

509

Beijing

2024-10-01

Recruiting

TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT

NCT06622031Hepatocellular Carcinoma, Portal Vein Tumor Thrombus, Systemic Therapy

DrugLenvatinib

Sun Yat-sen University

Not applicable

Beijing

2024-10-01

Recruiting

The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma

NCT06609850Recurrent Hepatocellular Carcinoma, Lenvatinib, Local Therapy, Ablation

DrugLenvatinb

Sun Yat-sen University

Not applicable

116

Beijing

2024-10-01

Recruiting

Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC

NCT06609876Hepatocellular Carcinoma, Microwave Ablation, Donafenib, Recurrent Tumor

DrugDonafenib

Sun Yat-sen University

Not applicable

108

Beijing

2024-10-01

By invitation

Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma

NCT06609239Asthma

DrugLunsekimig

Sanofi

Phase 2

900

Beijing, Changchun, Changsha, Chengde, Guangzhou, Guiyang, Hefei, Hohhot

2024-09-30

Recruiting

Peripheral Scoring Drug-coated Balloon in the Treatment of Hemodialysis Arteriovenous Fistula Stenosis

NCT06422845Arteriovenous Fistula Stenosis

DK Medical Technology (Suzhou) Co., Ltd.

Not applicable

328

Hefei, Beijing, Chongqing, Guanzhou, Huizhou, Shenzhen, Liuzhou, Nanning

2024-09-30

Active, closed

Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Adizutecan (ABBV-400) Moves Through the Body of Adult Participants With Unresectable Locally Advanced/Metastatic Colorectal Cancer

NCT06464692Colorectal Cancer

DrugTelisotuzumab Adizutecan

AbbVie

Phase 1

Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanchang, Shenyang, Hangzhou

2024-09-30

Recruiting

Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer

NCT06530303Colorectal Cancer, Colon Cancer, Rectum Cancer

DrugsTumor Infiltrating Lymphocytes·Aldesleukin·Fludarabine·Cyclophosphamide

Essen Biotech

Phase 1/2

Beijing

2024-09-29

Recruiting

A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients With SSTR+ GEP-Nens

NCT06732505Neuroendocrine Neoplasm

Drug[225Ac]Ac-DOTATATE

Peking University Cancer Hospital & Institute

Phase 1

Beijing

2024-09-29

Recruiting

Bactiseal Catheter Safety Registry Study

NCT06276543Hydrocephalus

Integra LifeSciences Corporation

Observational

200

Beijing, Guangzhou, Harbin, Wuhan, Shanghai, Chengdu

2024-09-29

By invitation

⁶⁸Ga-DPA in the Lung Cancer Diagnosis

NCT07023068Lung Cancers

Peking Union Medical College Hospital

Early Phase 1

Beijing

2024-09-28

Active, closed

Study on Ginkgo Biolba Extract Fifty and Mild Cognitive Impairment Associated With CSVD

NCT06495476Mild Cognitive Impairment

Beijing Tiantan Hospital

Phase 2/3

144

Beijing

2024-09-27

Recruiting

A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma

NCT06564272Ewing Sarcoma

DrugKC1036

Beijing Konruns Pharmaceutical Co., Ltd.

Phase 2

Beijing

2024-09-27

By invitation

A Study to Evaluate the Safety and Efficacy of Staged Bilateral Magnetic Resonance-Guided Focused Ultrasound Thalamotomy for the Treatment of Essential Tremor

NCT06676501Essential Tremor, Essential Tremor, Movement Disorders

Chinese PLA General Hospital

Not applicable

Beijing

2024-09-26

Active, closed

A Study in Patients With Myasthenia Gravis in China

NCT06700616Myasthenia Gravis

AstraZeneca

Observational

1,199

Beijing, Chengdu, Fuzhou, Guangzhou, Guiyang, Harbin, Hebei, Henan

2024-09-26

Recruiting

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

NCT06585787Alzheimer Disease

DrugKarXT

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

406

Beijing, Chongqing, Guangzhou, Shenzhen, Nanjing, Zhenjiang, Xi'an, Shanghai

2024-09-26

Active, closed

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

NCT06238622Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis

DrugNerandomilast

Boehringer Ingelheim

Phase 3

1,666

Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Hohhot, Jiaxing

2024-09-26

Active, closed

Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients

NCT06635447Breast Cancer

DrugsCapivasertib·Fulvestrant

AstraZeneca

Phase 3

293

Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Dalian, Deyang

2024-09-26

Active, closed

A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

NCT06660394Dravet Syndrome

DrugBexicaserin

Longboard Pharmaceuticals

Phase 3

108

Beijing, Guangzhou, Shenzhen Shi, Wuhan, Shanghai Shi

2024-09-25

Active, closed

Evaluate the Safety and Efficacy of Intrathecal Injection of RJK002 in Patients With Amyotrophic Lateral Sclerosis

NCT06493279Amyotrophic Lateral Sclerosis Als

DrugRJK002

RJK Biopharma Ltd

Phase 1

Beijing

2024-09-24

Recruiting

A Prospective, Multicenter, Observational Cohort Study Assessing the Efficacy and Safety of Radiotherapy-sensitized Immunotherapy in Advanced Breast Cancer

NCT06776861Advanced Breast Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Observational

150

Beijing

2024-09-24

Recruiting

A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)

NCT06530251Hepatocellular Carcinoma

DrugsAK127·AK130·Bevacizumab biosimilar·Cadonilimab

Akeso

Phase 1/2

280

Beijing, Jinan

2024-09-24

Recruiting

Pola-ZR2P in Previously Untreated DLBCL

NCT06664411Diffuse Large B-cell Lymphoma

Navy General Hospital, Beijing

Phase 2

Beijing

2024-09-24

Recruiting

Remote Ischemic Conditioning for Acute Ischemic Stroke Treated With Mechanical Thrombectomy（RECAST-MT）

NCT06559241Acute Ischemic Stroke, Anterior Circulation Brain Infarction

Capital Medical University

Phase 3

2,105

Suzhou, Taihe Chengguanzhen, Tongling, Beijing, Fuzhou, Zhangzhou, Shenzhen, Nanning

2024-09-23

Recruiting

The Efficacy and Safety of Combining Probiotic VSL#3 With Vedolizumab for the Treatment of Moderate Ulcerative Colitis

NCT06609447Ulcerative Colitis

DrugVedolizumab

Second Affiliated Hospital, Zhejiang University, School of Medicine

Phase 4

100

Beijing, Chongqing, Guangzhou, Wuhan, Xi’an, Chengdu, Hangzhou, Huzhou

2024-09-21

Recruiting

Safety and Efficacy Study of PUMCH-E101 Injection in Subjects with RDH12 Retinopathy

NCT06749639Inherited Retinal Diseases

Peking Union Medical College Hospital

Early Phase 1

Beijing

2024-09-20

Recruiting

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

NCT06469944Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer

DrugsPatritumab deruxtecan·Xeloda·Sacituzumab tirumotecan·Leucovorin

Merck Sharp & Dohme LLC

Phase 1/2

160

Beijing, Fuzhou, Xiamen, Zhengzhou, Nanchang, Shanghai, Ürümqi, Hangzhou

2024-09-20

Recruiting

Hydration Guided by Remote Dielectric Sensing (ReDS) System for Preventing Acute Kidney Injury in Elderly Patients With Renal Insufficiency for Coronary Angiography and Intervention

NCT07394959Coronary Artery Disease, Chronic Kidney Disease, Elderly

Chinese PLA General Hospital

Not applicable

320

Beijing

2024-09-20

Not yet open

To Evaluate Recombinant Human Follicle Stimulating Hormone-CTP Fusion Protein Injection or Placebo Combined With Chorionic Gonadotropin for Injection

NCT06561594Idiopathic Hypogonadotropic Hypogonadism

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 3

Hefei, Beijing, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Nanjing, Nanchang

2024-09-20

Not yet open

CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML

NCT06470841Acute Myeloid Leukemia

Navy General Hospital, Beijing

Phase 2

Beijing

2024-09-20

Recruiting

Safety Evaluation of Gene Therapy Drug in the Treatment of Primary Hypertriglyceridemic Patients With Recurrent Pancreatitis

NCT05860569Hypertriglyceridemia, Familial

GeneCradle Inc

Phase 1

Beijing

2024-09-20

Recruiting

Outcomes and Risk Factors of Different Treatment Strategies for Neuro-co-cardiological Diseases and Post-cardiac Surgery Cerebrovascular Diseases

NCT07012668Neuro-co-cardiological Diseases, Post-cardiac Surgery Cerebrovascular Diseases, Vascular Lesion

Beijing Anzhen Hospital

Observational

2,000

Beijing

2024-09-19

By invitation

Comparative Study of Perioperative Cardiac Injury in Patients With Functional Adrenal Tumors

NCT07182175Primary Aldosteronism, Adrenal Tumor, Cushing s Syndrome, Pheochromocytoma/Paraganglioma (PPGL)

Peking University First Hospital

Observational

150

Beijing

2024-09-19

Recruiting

Clinical Study of the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Prurigo Nodularis

NCT06554509Prurigo Nodularis

DrugSHR-1819

Guangdong Hengrui Pharmaceutical Co., Ltd

Phase 2/3

423

Beijing

2024-09-19

Recruiting

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

NCT06635148Geographic Atrophy, Macular Degeneration

Janssen Research & Development, LLC

Phase 2/3

274

Beijing, Chengdu, Shanghai

2024-09-19

Recruiting

A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.

NCT06927466Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

DrugB019

Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.

Phase 1

Beijing, Nanchang, Shanghai, Suzhou, Wuhan, Xuzhou

2024-09-19

Active, closed

A Phase 3, Multicenter, Randomized, Double-Masked, Sham-Controlled Clinical Trial for Leber's Hereditary Optic Neuropathy (LHON) Associated With ND4 Mutation

NCT07406854Leber Hereditary Optic Neuropathy (LHON)

Wuhan Neurophth Biotechnology Limited Company

Phase 3

Beijing

2024-09-19

Recruiting

Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)

NCT06726421Renal Cell Carcinoma (Kidney Cancer), Kidney Cancer Metastatic, Renal Cell Carcinoma Metastatic

Sun Yat-sen University

Phase 3

252

Fuzhou, Guangzhou, Wuhan, Changchun, Chengdu, Wenzhou, Beijing, Shanghai

2024-09-18

Active, closed

A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06589986Moderately to Severely Active Ulcerative Colitis

DrugAfimkibart

Hoffmann-La Roche

Phase 3

400

Beijing, Binzhou, Changchun, Chengdu, Fuzhou, Guangzhou, Hefei, Huizhou

2024-09-17

Active, closed

A Study of Obexelimab in Patients With Systemic Lupus Erythematosus

NCT06559163Systemic Lupus Erythematosus

DrugObexelimab

Zenas BioPharma (USA), LLC

Phase 2

190

Hefei, Beijing, Guangzhou, Shenzhen, Shijiazhuang, Nanchang, Pudong, Shanghai

2024-09-17

Active, closed

A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy

NCT06537999Multifocal Motor Neuropathy

DrugClaseprubart

Dianthus Therapeutics

Phase 2

Beijing, Shanghai

2024-09-17

Active, closed

Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

NCT06333951Thoracic Tumors, Non-small Cell Lung Cancer

DrugsAnvumetostat·Sotorasib·Pemetrexed·Paclitaxel

Amgen

Phase 1

Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changchun, Chengdu, Beijing

2024-09-17

Not yet open

Factors Affecting Selection of Leadless Pacemaker and Atrioventricular Synchronous Pacing Status

NCT06587672Pacemaker, Atrioventricular Block, Clinical Trials, Pacing

Xiaohan Fan

Observational

112

Beijing

2024-09-15

Recruiting

A Clinical Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in The Treatment of Upper Limb Spasticity in Adults

NCT06783114Upper Limb Spasticity

DrugsRecombinant Botulinum Toxin Type A·Botox

Chongqing Claruvis Pharmaceutical Co., Ltd.

Phase 2/3

254

Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Kaifeng, Wuhan, Huai'an

2024-09-14

Recruiting

Distribution of Mood and Personality Characteristics and Their Influence on Treatment Compliance

NCT07101796Personality, Patient Compliance, Anxiety, Depression

Peking University First Hospital

Observational

200

Beijing

2024-09-14

Recruiting

Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers

NCT06580574Gastric Cancer, Colon Cancer, MSI-H, DMMR Cancer

Peking University

Phase 2

Beijing

2024-09-13

Recruiting

Neoadjuvant Immunochemotherapy in PD-L1-negative LACC

NCT06288360Cervical Cancer, Locally Advanced Cervical Cancer, PD-L1 Negative, Neoadjuvant Chemoimmunotherapy

DrugsPaclitaxel-albumin·Camrelizumab·Cisplatin

Tongji Hospital

Phase 2

Hefei, Beijing, Chongqing, Lanzhou, Nanning, Wuhan, Changsha, Shenyang

2024-09-12

Recruiting

Individualized Exploration of Aerobic Exercise-assisted Treatment of Depression

NCT06594588Depression - Major Depressive Disorder

Peking University

Not applicable

Beijing

2024-09-12

Active, closed

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

NCT06586515Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer

DrugsLeucovorin·Irinotecan·Cetuximab·Adrucil

Eli Lilly and Company

Phase 1

630

Beijing, Harbin, Shanghai

2024-09-12

Recruiting

A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

NCT06572384Lung Diseases, Interstitial

DrugBelimumab

GlaxoSmithKline

Phase 3

440

Beijing, Chengdu, Guangzhou, Hangzhou, Mianyang, Nanjing, Nanning, Shanghai

2024-09-11

Recruiting

Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors

NCT06596915Non-Small Cell Lung Cancer, Pancreatic Adenocarcinoma, Breast Cancer, Melanoma

Shandong Boan Biotechnology Co., Ltd

Phase 1

167

Beijing

2024-09-11

Recruiting

A Study of the Safety and Tolerability of GA in the Treatment of Patients With Refractory Neuropathic Pain

NCT06596681Pain, Intractable

Beijing Tiantan Hospital

Early Phase 1

Beijing

2024-09-11

Recruiting

Postoperative Complications Following Skull Base Tumor Resection

NCT06587906Skull Base Tumor, Postoperative Complications

Beijing Tiantan Hospital

Observational

122

Beijing

2024-09-10

Recruiting

TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer

NCT06532799Stomach Cancer, Stomach Cancer Recurrent, Stomach Cancer, Adenocarcinoma, Esophageal Cancer

DrugsCyclophosphamid·Tumor Infiltrating Lymphocytes·Aldesleukin·Fludarabine

Essen Biotech

Phase 1/2

Beijing

2024-09-10

Not yet open

Thermal Ablation Vs Thyroidectomy for Large Benign Thyroid Nodules

NCT06607133Benign Thyroid Nodules

Ming-an Yu

Observational

300

Beijing

2024-09-10

Recruiting

Outcomes for Anesthesiologist-Led Care of Analgesic Protocol in Anorectal Surgery

NCT06015165Postoperative Pain

China-Japan Friendship Hospital

Not applicable

216

Beijing

2024-09-10

Recruiting

Phase II Clinical Trial of PD-L1 in Combination With Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy With or Without Radiotherapy for Advanced Triple-negative Breast Cancer.

NCT06771609Advanced Triple-negative Breast Cancer

DrugAdebrelimab

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2

150

Beijing

2024-09-10

Recruiting

A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer

NCT06692166Cervical Cancer

Drug9MW2821

Mabwell (Shanghai) Bioscience Co., Ltd.

Phase 3

420

Beijing, Shanghai

2024-09-10

Recruiting

Efficacy and Safety of SR1375 in Adult Patients With CAP

NCT06577558Community-acquired Pneumonia

Shanghai SIMR Biotechnology Co., Ltd.

Phase 2

240

Fuyang, Beijing, Zhangzhou, Gaozhou, Guangzhou, Shantou, Yulin, Shijiazhuang

2024-09-10

Recruiting

ICAS Screen Based on RIC

NCT06610578Intracranial Atherosclerosis

Xuanwu Hospital, Beijing

Observational

2,100

Beijing

2024-09-05

Recruiting

Online Adaptive Radiotherapy for Cervical Cancer

NCT06562166Cervical Cancer

Peking Union Medical College Hospital

Phase 2

124

Beijing

2024-09-05

Active, closed

A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

NCT06550076Plaque Psoriasis

DrugZasocitinib

Takeda

Phase 3

2,099

Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Wuhan, Zhenjiang, Shanghai

2024-09-04

Recruiting

Study of AXT-1003 in Subjects With Advanced Malignant Tumors.

NCT06484985Non-Hodgkin Lymphoma, Advanced Solid Tumor

Axter Therapeutics (Beijing) Co., Ltd

Phase 1

Beijing, Changsha, Fuzhou, Guangzhou, Shanghai

2024-09-04

Recruiting

A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer

NCT06631989EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer

DrugWSD0922-FU

Wayshine Biopharm, Inc.

Phase 1/2

100

Hefei, Beijing, Guangzhou, Zhengzhou, Jinan, Shanghai, Chengdu, Tianjin

2024-09-04

Recruiting

Er:YAG Laser and Air Polishing Application in Periodontal Treatment

NCT06574802Periodontitis

Beijing Chao Yang Hospital

Not applicable

Beijing

2024-09-04

Recruiting

Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.

NCT06482905High-grade Glioma, WHO Grade Ⅳ Glioma

Tcelltech Inc.

Phase 1

Beijing

2024-09-04

Active, closed

Efficacy and Safety of PJ009 in Patients With Short Bowel Syndrome Requiring Parenteral Nutrition

NCT06512584Short Bowel Syndrome

Chongqing Peg-Bio Biopharm Co., Ltd.

Phase 3

Beijing, Chongqing, Guangzhou, Changsha, Nanjing, Qingdao, Shanghai, Xi’an

2024-09-03

Recruiting

First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors

NCT06554795Solid Tumor, Adult

DualityBio Inc.

Phase 1/2

360

Hefei, Beijing, Jilin City, Chongqing, Fuzhou, Nanning, Harbin, Luoyang

2024-09-03

Recruiting

A RWS of SC MTX in Chinese RA Patients

NCT07463937Rheumatoid Arthritis (RA)

Peking University People's Hospital

Observational

10,000

Beijing

2024-09-03

Recruiting

A Phase I Study on Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SXRN Plasmid DNA Technique in Patients With Advanced Solid Tumors

NCT06736275Advanced Cancer, Cachexia

DrugSXRN

Jiangsu Nutai Biologics Co., Ltd

Early Phase 1

Beijing

2024-09-02

Recruiting

PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer

NCT06549855Endometrial Cancer, Endometrioid Carcinoma, Mismatch Repair Deficiency

DrugSintilimab

Peking University People's Hospital

Not applicable

Beijing

2024-09-02

Recruiting

Treatment of ACuTe Coronary Syndromes With Low-dose colchICine

NCT06215989Acute Coronary Syndrome, Unstable Angina, ST Elevation Myocardial Infarction, Non ST Segment Elevation Myocardial Infarction

DrugsColchicine Pill·Colchicine

Beijing Anzhen Hospital

Not applicable

6,574

Beijing

2024-09-02

Recruiting

Neural Mechanisms and Clinical Applications of DBS for Modulating Sleep Dysregulation in PD

NCT06914466Deep Brain Stimulation, Parkinson's Disease and Parkinsonism, Sleep Disorder

Xuanwu Hospital, Beijing

Observational

Beijing

2024-09-01

Recruiting

Establishment of Screening Pathway for High-Risk Population of Type 1 Diabetes

NCT07468474Type 1 Diabetes Mellitus

Peking University First Hospital

Observational

340

Beijing

2024-09-01

Recruiting

Low-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation

NCT06108414Atrial Fibrillation, Anticoagulant Adverse Reaction, Stroke, Major Adverse Cardiac Events

DrugRivaroxaban

China National Center for Cardiovascular Diseases

Phase 4

4,374

Beijing

2024-09-01

Recruiting

Automated Bone Age Estimation From Noncontrast Abdominal CT Using Deep Learning

NCT07162168Bone Aging, Osteoporosis Diagnosis

Peking University People's Hospital

Observational

3,000

Beijing

2024-09-01

Not yet open

Phase 1 Trial of KH801

NCT06364501Advanced Solid Tumors

Beijing Kanghong Biopharmaceutical Co., Ltd.

Phase 1

Beijing, Guangzhou, Jinan, Chengdu

2024-09-01

Recruiting

Clinical Study of Irinotecan Liposome (II)-Based Combination Treatment for Irinotecan-resistant Colorectal Cancer.

NCT07044921Colorectal Cancer Metastatic

DrugsIrinotecan liposomes·Cetuximab

Chinese PLA General Hospital

Phase 2

Beijing

2024-09-01

By invitation

A Study to Evaluate the Safety and Efficacy of HB0052 in Patients With Advanced Solid Tumors

NCT06992687Solid Tumors

Shanghai Huaota Biopharmaceutical Co., Ltd.

Phase 1/2

Beijing

2024-09-01

Recruiting

Hypofractionated Online Adaptive Radiotherapy of Breast Cancer

NCT06568705Breast Cancer

Peking Union Medical College Hospital

Phase 2

Beijing

2024-09-01

Recruiting

First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma

NCT05188859Mesothelioma, Malignant, Mesothelioma, Malignant Pleural, Mesothelioma Malignant Advanced

DrugsAnlotinib·Sintilimab·Pemetrexed·Cisplatin

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2

Taiyuan, Beijing

2024-09-01

Not yet open

Chidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.

NCT06563778Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma

DrugsBrentuximab Vedotin·Decitabine·Bendamustine·Chidamide

Chinese PLA General Hospital

Phase 2

100

Beijing

2024-09-01

Active, closed

Exploring the Expression Level of Cadherin 6 Protein (CDH6) in Primary Malignant Bone Tumor Specimens and Its Clinical Application in Prognosis Assessment

NCT06850506Sarcoma, Sarcoma, Bone, Ewing Sarcoma, Osteosarcoma

Peking University People's Hospital

Observational

Beijing

2024-09-01

Not yet open

Deep Brain Stimulation of the Dentate Nucleus for Motor Rehabilitation After Stroke

NCT06498934Stroke, Upper Extremity Paresis

Beijing Municipal Administration of Hospitals

Not applicable

Beijing

2024-09-01

Recruiting

Golidocitinib Plus CHOP in Newly Diagnosed PTCL

NCT06739265Peripheral T-cell Lymphoma

DrugsCHOP·Golidocitinib

Peking Union Medical College Hospital

Phase 1/2

Beijing

2024-09-01

Recruiting

Fasting Effects on Metabolism and Immunity Study in Human

NCT06779201Fasting

Xuanwu Hospital, Beijing

Not applicable

Beijing

2024-09-01

By invitation

A Study of the Efficacy and Safety of Non-ablative Fractional Laser in the Treatment of Thyroidectomy Scars

NCT07037264Scars After Surgical Intervention

Chinese Medical Association

Not applicable

120

Beijing

2024-09-01

Recruiting

Deep Learning for Automated Discrimination Between Stage T1-T2 and T3 Renal Cell Carcinoma on Contrast-Enhanced CT

NCT07166445Carcinoma, Renal Cell, Diagnostic Imaging, Pathology, Deep Learning

Peking University First Hospital

Observational

1,000

Beijing

2024-09-01

By invitation

[68Ga]Ga-P17-079 in the Diagnosis and Treatment of Metastatic Prostate Cancer

NCT06864572Metastatic Prostate Cancer (mPC)

Peking Union Medical College Hospital

Early Phase 1

Beijing

2024-09-01

Active, closed

A Clinical Trial of Vascular Interventional Robotic System for Cerebral Angiography

NCT07182188Crerbral Angiography

Peking Union Medical College Hospital

Not applicable

660

Beijing

2024-09-01

Not yet open

Clinical Multicenter Randomized Controlled Study of Non-invasive Brain Oscillation Modulation in the Treatment of AD-MCI Patients

NCT06470074AD-MCI

Xuanwu Hospital, Beijing

Not applicable

124

Beijing

2024-09

Not yet open

Clinical Multicenter Randomized Controlled Study of Simultaneous Cognitive Training With Transcranial Magnetic Stimulation in the Treatment of VaD-MCI Patients

NCT06470113VaD-MCI

Xuanwu Hospital, Beijing

Not applicable

164

Beijing

2024-09

Not yet open

A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory POEMS Syndrome

NCT06518876POEMS Syndrome

Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Phase 1

Beijing

2024-08-31

Active, closed

A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.

NCT06116136MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer

DrugsS095029·Keytruda·Pembrolizumab

Servier Bio-Innovation LLC

Phase 1/2

Beijing, Harbin, Zhengzhou, Shenyang, Jinan, Shanghai, Hangzhou

2024-08-31

Recruiting

Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

NCT06509009Nasopharyngeal Carcinoma by AJCC V8 Stage

DrugNimotuzumab

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2

Beijing

2024-08-30

Recruiting

Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment

NCT06932471Paroxysmal Nocturnal Hemoglobinuria

DrugMY008211A

Wuhan Createrna Science and Technology Co., Ltd

Phase 3

Beijing

2024-08-30

Active, closed

Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

NCT06564142Immunoglobulin A Nephropathy

DrugPovetacicept

Alpine Immune Sciences Inc, A Subsidiary of Vertex

Phase 3

605

Beijing, Cangzhou, Changchun, Changzhi, Chengdu, Chongqing, Dongguan, Foshan

2024-08-30

Active, closed

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

NCT06531824Kidney Disease, Chronic

DrugsVicadrostat·Dapagliflozin

Boehringer Ingelheim

Phase 3

8,371

Anshan, Beijing, Changzhi, Chaoyang, Chengdu, Chifeng, Chongqing, Foshan

2024-08-30

Recruiting

Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy

NCT06932744Paroxysmal Nocturnal Haemoglobinuria (PNH)

DrugsMY008211A·Eculizumab

Wuhan Createrna Science and Technology Co., Ltd

Phase 3

Beijing, Tianjin

2024-08-30

Recruiting

Unveiling the Neural Mechanisms of 5-HT7 in Sleep Apnea Induced by Arousal Dysregulation

NCT06608888Obstructive Sleep Apnea

Beijing Tsinghua Chang Gung Hospital

Observational

140

Beijing

2024-08-30

Recruiting

Study With [225Ac]Ac-FL-020 in mCRPC Participants

NCT06492122Metastatic Castration-resistant Prostate Cancer

DrugBlood samples for PK

Full-Life Technologies UK Limited

Phase 1

Beijing, Shanghai

2024-08-30

Recruiting

Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL

NCT06503263Diffuse Large B-cell Lymphoma

DrugZanubrutinib

Navy General Hospital, Beijing

Phase 2

240

Beijing

2024-08-30

Recruiting

Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.

NCT06440057Neuroendocrine Carcinoma

DrugZG006

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 1/2

Beijing

2024-08-29

Recruiting

Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET

NCT06552429Essential Thrombocythemia

DrugPeginterferon α-2b

Xiamen Amoytop Biotech Co., Ltd.

Phase 2

Beijing, Fujian, Guangzhou, Harbin, Henan, Shanghai, Zhejiang

2024-08-29

Recruiting

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

NCT06452277Advanced Non-small Cell Lung Cancer, HER2 Mutation

DrugsSevabertinib·Pemetrexed·Cisplatin·Carboplatin

Bayer

Phase 3

444

Beijing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin, Wuhan, Changsha

2024-08-28

Active, closed

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

NCT06486441Endometrial Cancer

DrugsAdriamycin·Sacituzumab Govitecan·Taxol·Doxorubicin

Gilead Sciences

Phase 3

640

Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangxi Zhuang Autonomous Region, Guangzhou, Hangzhou

2024-08-28

By invitation

Long-term, High Blood Flow Hemoadsorption Therapy in Patients Undergoing Maintenance Hemodialysis

NCT06574425Chronic Kidney Diseases, Hemodialysis

Dongliang Zhang, MD

Phase 4

Beijing

2024-08-28

Active, closed

Phase IIa Study Evaluating AZD7798 in Crohn's Disease

NCT06450197Moderate to Severe Crohn's Disease

DrugAZD7798

AstraZeneca

Phase 2

120

Beijing, Chengdu, Guangzhou, Hangzhou, Nanchang, Nanjing, Wuhan

2024-08-28

Active, closed

Volrustomig Priming Regimens Exploratory Phase II Platform Study

NCT06448754Non-small Cell Lung Cancer

DrugsVolrustomig·Ramucirumab·Pemetrexed·Paclitaxel

AstraZeneca

Phase 2

194

Beijing, Hangzhou, Jinan, Yantai, Zhengzhou

2024-08-27

Active, closed

ARISE-A Chinese Real-world Study of Rimegepant for the Acute Treatment of Migraine

NCT06439628Migraine

DrugRimegepant

Chinese PLA General Hospital

Observational

3,000

Beijing, Hangzhou

2024-08-27

Active, closed

Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment

NCT06502977Extensive Stage Small Cell Lung Cancer

DrugTarlatamab

Amgen

Phase 2

Beijing, Chongqing, Fuzhou, Guangzhou, Jiangmen, Harbin, Wuhan, Tianjin

2024-08-27

Active, closed

A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)

NCT06564311Relapsing Multiple Sclerosis

DrugObexelimab

Zenas BioPharma (USA), LLC

Phase 2

Beijing, Suzhou, Tianjin, Ürümqi, Wuhan

2024-08-26

Recruiting

Efficacy of ICG-based NIR Imaging in Intralesional Curettage of Giant Cell Tumors of Bone in Limbs: a Prospective, Single-center, Single-arm, Open Study

NCT06647901Giant Cell Tumor of Bone

Tang Xiaodong

Phase 1/2

Beijing

2024-08-23

Active, closed

A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease

NCT06610526Chronic Kidney Disease

DrugDapagliflozin

AstraZeneca

Phase 4

731

Beijing, Changchun, Dongguan, Foshan, Fuyang, Fuzhou, Ganzhou, Harbin

2024-08-23

Recruiting

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

NCT06535607Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)

DrugsVolrustomig·Adrucil·Paclitaxel·Cisplatin

AstraZeneca

Phase 2

257

Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dongguan

2024-08-22

Recruiting

TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer

NCT06532812Breast Cancer, Breast Carcinoma, Breast Cancer Metastatic, Breast Cancer Triple Negative

DrugsCyclophosphamid·Tumor Infiltrating Lymphocytes·Aldesleukin·Fludarabine

Essen Biotech

Phase 1/2

Beijing

2024-08-22

Recruiting

China Stroke Primary Prevention Trial 2 for Participants With H-type Hypertension and MTHFR 677 CC/CT Genotype (CSPPT2-CC/CT)

NCT04974138Hypertension, MTHFR 677 CC or CT Genotype, Elevated Plasma Homocysteine (Hcy≥10µmol/L), Insufficient Plasma Folate Levels (<12ng/mL)

DrugsAmlodipine besylate and folic acid·Amlodipine besylate·Amlodipine

Shenzhen Ausa Pharmed Co.,Ltd

Phase 4

32,000

Bengbu, Bozhou, Chizhou, Fuyang, Beijing, Yangjiang, Guiyang, Huaihua

2024-08-22

Recruiting

China Stroke Primary Prevention Trial 2 for Participants With Hypertension and MTHFR 677 TT Genotype

NCT04974151Hypertension, MTHFR 677 TT Genotype

DrugsAmlodipine besylate and folic acid·Amlodipine besylate·Amlodipine

Shenzhen Ausa Pharmed Co.,Ltd

Phase 4

24,000

Bengbu, Bozhou, Chizhou, Fuyang, Beijing, Yangjiang, Guiyang, Huaihua

2024-08-22

By invitation

Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China

NCT06712017Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Non-Resectable

GrandPharma (China) Co., Ltd.

Observational

100

Guangzhou, Jinan, Xi’an, Beijing, Shanghai

2024-08-22

By invitation

A Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for EC

NCT06863831Esophageal Squamous Cell Carcinoma (ESCC)

DrugsYishen Qutong·Yishen Qutong Simulant

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Not applicable

536

Beijing

2024-08-22

Recruiting

Large Segmentation Radiotherapy ± Deep Inspiration Breath Hold(DIBH) for Left Breast Cancer

NCT06660628Breast Cancer

Peking Union Medical College Hospital

Not applicable

348

Beijing

2024-08-21

Recruiting

A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT06290141Chronic Inflammatory Demyelinating Polyneuropathy

DrugsRiliprubart·IVIG

Sanofi

Phase 3

160

Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Jiazhuang, Jinan, Nanchang

2024-08-21

Recruiting

Sitagliptin or BeiDouGen Capsule Improve the Pregnancy Outcome in Patients with PCOS

NCT06587698Polycystic Ovarian Syndrome

DrugSitagliptin

Peking University Third Hospital

Not applicable

300

Beijing

2024-08-21

Not yet open

Priority-Matching Correction Technique in Degenerative Lumbar Scoliosis

NCT06470165Degenerative Lumbar Disease, Scoliosis, Degenerative Scoliosis

Xuanwu Hospital, Beijing

Not applicable

200

Beijing

2024-08-21

Recruiting

A Study of [177Lu] Lu-PSMA-XT Injection in Patients With Metastatic Prostate Cancer

NCT07096128mCRPC

Jinming Zhang

Phase 1

Beijing

2024-08-20

Recruiting

Research on Early Diagnosis and Clinical Transformation of Nuclide Probe Based on Bioorthogonal-gastric Cancer Mucin Target Visualization

NCT06429891Solid Tumor

DrugFluorodeoxyglucose

Hua Zhu

Not applicable

Beijing

2024-08-20

Recruiting

TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer

NCT06538012Lung Cancer, Lung Cancer Metastatic, Lung Cancer, Non-small Cell, Lung Cancer Recurrent

DrugsTumor Infiltrating Lymphocytes·Aldesleukin·Fludarabine·Cyclophosphamide

Essen Biotech

Phase 1/2

Beijing

2024-08-20

Active, closed

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

NCT06461897Atopic Dermatitis

DrugsUpadacitinib·Dupilumab

AbbVie

Phase 3

699

Beijing, Yuzhong District, Xiamen, Shenzhen, Zhengzhou, Changsha, Dalian, Chengdu

2024-08-19

By invitation

Smart Technology Facilitated Patient-centered Venous Thromboembolism Management

NCT06350331Venous Thromboembolism, Digital Health, Health Education

Navy General Hospital, Beijing

Not applicable

256

Beijing

2024-08-17

Recruiting

Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer

NCT06685276Colorectal Cancer Metastatic

DrugsFruquintinib·Chidamide·Sintilimab

Dai, Guanghai

Phase 2

Beijing

2024-08-16

Recruiting

A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer

NCT07122414Non-muscle Invasive Bladder Cancer (NMIBC)

DrugFL115

Suzhou Forlong Biotechnology Co., Ltd

Phase 1/2

Beijing, Fuzhou, Wenzhou, Changsha, Nanjing, Suzhou, Qingdao, Chengdu

2024-08-16

Recruiting

A Phase I Study of XS-02 Capsules in Patients With Advanced Solid Tumors

NCT06531486Solid Tumor, Ovarian Cancer, Breast Cancer, Endometrial Cancer

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Phase 1

Beijing

2024-08-15

Not yet open

Effect of Aerobic Interval Training on Atrial Fibrillation Burden

NCT06491329Atrial Fibrillation, Cardiac Rehabilitation

Navy General Hospital, Beijing

Not applicable

156

Beijing

2024-08-15

Recruiting

Phase II Study of FCN-159 in NF2 Nerve Sheath Tumors

NCT06553365Nerve Sheath Tumor

DrugLuvometinib

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2

Beijing

2024-08-15

By invitation

Application of FAPI Visualization in the Assessment of Right Ventricular Dysfunction Due to Volume Overload

NCT06663566Right Heart Insufficiency, Tricuspid Regurgitation

Beijing Anzhen Hospital

Observational

Beijing

2024-08-15

Recruiting

Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer

NCT06708858Advanced Biliary Tract Cancer

DrugsSurufatinib·Durvalumab·Gemcitabine·Cisplatin

Dai, Guanghai

Phase 2

Beijing

2024-08-15

Recruiting

One-Month DAPT in CABG Patients

NCT05997693Chronic Coronary Disease

DrugsTicagrelor·Aspirin

Weill Medical College of Cornell University

Phase 3

700

Shanghai, Changchun, Beijing

2024-08-15

Recruiting

Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC

NCT06467617Non Small Cell Lung Cancer

DrugAdebrelimab

Beijing Chest Hospital, Capital Medical University

Phase 2

Beijing

2024-08-14

Active, closed

A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT06508658Diffuse Large B-Cell Lymphoma

DrugsEpcoritamab·Lenalidomide·Rituximab·Oxaliplatin

Genmab

Phase 3

379

Beijing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan

2024-08-13

Recruiting

Weight Cycling on Hyperandrogenemia and Insulin Resistance in Polycystic Ovary Syndrome

NCT06545721Polycystic Ovary Syndrome

Peking Union Medical College Hospital

Not applicable

425

Beijing

2024-08-13

Recruiting

Scoring Balloon and High Pressure Balloon in the Treatment of Arteriovenous Graft Stenosis

NCT06503692Arteriovenous Graft Stenosis

DK Medical Technology (Suzhou) Co., Ltd.

Not applicable

140

Beijing, Guangzhou, Shenzhen, Zhengzhou, Nanjing, Shanghai

2024-08-13

Recruiting

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

NCT06467357Biliary Tract Cancer

DrugsRilvegostomig·Trastuzumab deruxtecan·Durvalumab·Gemcitabine

AstraZeneca

Phase 3

620

Beijing, Bengbu, Changchun, Changde, Changsha, Chengdu, Chongqing, Fuzhou

2024-08-12

Active, closed

A Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy

NCT06516068Obstructive Hypertrophic Cardiomyopathy

DrugHRS-1893

Shandong Suncadia Medicine Co., Ltd.

Phase 2

Beijing

2024-08-11

Not yet open

Efficacy of Deep Brain Stimulation(DBS) for Treatment-Resistant Depression(TRD)

NCT06542900Treatment Resistant Depression

Xuanwu Hospital, Beijing

Not applicable

Beijing

2024-08-10

Recruiting

Evaluate the Efficacy and Safety of Amino Acid (15) Peritoneal Dialysis Solution in Peritoneal Dialysis Patients with Malnutrition.

NCT06597201End Stage Renal Disease (ESRD)

DrugAmino acid (15) peritoneal dialysis

Chengdu Qingshan Likang Pharmaceutical Co., Ltd

Phase 4

400

Hefei, Beijing, Wuhan, Changsha, Chengdu, Chongqing, Ganzhou, Guangdong

2024-08-09

Recruiting

ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI

NCT06388031Non-small Cell Lung Cancer

DrugKeytruda

Peking Union Medical College Hospital

Phase 2

Beijing

2024-08-09

Active, closed

Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

NCT06332534Crohn's Disease

DrugUpadacitinib

AbbVie

Phase 3

111

Beijing, Guangzhou, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai, Hangzhou

2024-08-08

Recruiting

Polymeric Micellar Paclitaxel-Based Combination Therapy for Advanced Biliary Tract Cancer

NCT07159204Biliary Tract Cancer (BTC)

Peking Union Medical College Hospital

Phase 2

Beijing

2024-08-07

Recruiting

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

NCT06549595Untreated Follicular Lymphoma

DrugsSurovatamig·R-Chop

AstraZeneca

Phase 3

1,018

Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou

2024-08-07

Active, closed

Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib

NCT06531109Alopecia Areata

DrugRitlecitinib

Pfizer

Observational

450

Beijing, Changchun, Changsha, Guangzhou, Shanghai

2024-08-07

Recruiting

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

NCT06445972Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer

DrugsPatritumab deruxtecan·Ramucirumab·Sacituzumab tirumotecan·Paclitaxel

Merck Sharp & Dohme LLC

Phase 1/2

210

Beijing, Fuzhou, Xiamen, Zhengzhou, Nanchang, Shanghai, Ürümqi, Hangzhou

2024-08-07

Recruiting

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

NCT06416410Advanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer

DrugsJAB-3312·Glecirasib·Pemetrexed·Tislelizumab

Allist Pharmaceuticals, Inc.

Phase 3

392

Hefei, Beijing, Fuzhou, Guangzhou, Shenzhen, Nanning, Cangzhou, Haerbin

2024-08-07

Recruiting

Al18F-NOTA-LM3 PET/CT in Patients With Pheochromocytoma and Paraganglioma

NCT07288931Pheochromocytoma/Paraganglioma (PPGL)

DrugsDiagnostic Test: 68Ga-DOTATATE·Diagnostic Test: Al18F-NOTA-LM3

Peking Union Medical College Hospital

Not applicable

Beijing

2024-08-06

Active, closed

Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China

NCT06332014Osteoporosis

DrugsProlia·Denosumab

Amgen

Phase 4

102

Beijing, Chongqing, Guangzhou, Harbin, Huaian, Nanjing, Suzhou, Xuzhou

2024-08-06

Recruiting

Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer

NCT06433609Advanced Breast Cancer

DrugsSHR-A1921·SHR-A2102·Trastuzumab Rezetecan·Adebrelimab

Beijing GoBroad Hospital

Phase 2

113

Beijing

2024-08-05

Active, closed

Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension

NCT06492291Hypercholesterolemia

DrugsEnlicitide Decanoate·Enlicitide

Merck Sharp & Dohme LLC

Phase 3

3,000

Beijing, Chongqing, Guangzhou, Huizhou, Shenzhen, Jingzhou, Wuhan, Changsha

2024-08-05

Active, closed

Iptacopan in Patients With ANCA Associated Vasculitis

NCT06388941Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis

DrugsIptacopan·Rituximab

Novartis Pharmaceuticals

Phase 2

Shijiazhuang, Zhengzhou, Beijing

2024-08-05

Recruiting

Trial of JYB1904 in Chronic Spontaneous Urticaria.

NCT06509334Chronic Spontaneous Urticaria

DrugsOzureprubart·Omalizumab

Jemincare

Phase 2

135

Beijing

2024-08-04

Active, closed

Study of CM310 in Adolescent Subjects With Atopic Dermatis

NCT06495229Atopic Dermatitis

DrugStapokibart

Keymed Biosciences Co.Ltd

Phase 3

180

Beijing

2024-08-02

Recruiting

POASAC Study (Preoperative Anemia Severity and Classification Study)

NCT06499974Anemia

Peking Union Medical College Hospital

Observational

1,000

Wuhu, Beijing, Zhangzhou, Zunyi, Chifeng, Hohhot

2024-08-02

Recruiting

Clinical Study on the Effectiveness of Diverse Segments Defocus Optimization in Spectacle Lenses for Slowing Myopia Progression

NCT07323251Children With Myopia, Treatment, Multizone Lens Design for Myopic Defocus, Visual Quality

Beijing Tongren Hospital

Not applicable

120

Beijing

2024-08-02

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/beijing?page=7

Query this register directly

GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 09 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5,576 of those studies with a site in Beijing.

How many clinical trials are recruiting in Beijing?

3,389 of the 5,576 studies on this page are recruiting new participants as of the 09 Nov 2026, 03:17 UTC sync. A further 990 have not yet opened recruitment, 1,019 are active but closed to new participants, and 178 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.